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Isotope ratios (IRs) are a measure of the variation in abundance of light isotopes versus 
heavy isotopes of an element, e.g. 1H/2H,12C/13C, and 14N/15N. Because IRs change as a 
molecule undergoes certain chemical and physical processes, they represent unique 
fingerprints that can be used to trace the source of a chemical compound. Current 
techniques for determination of IRs each have major limitations, such as loss of structural 
information, vulnerability to contamination, high cost, large sample size requirements, low 
precision, limited applicability, and lengthy analysis. Fast Isotope Ratio Mass 
Spectrometry (FIRMS) was developed as a next-generation analytical technique for robust 
measurement of IRs using tandem mass spectrometric data. Based on the FIRMS nonlinear 
mathematical model, the difference between predicted and experimental tandem mass 
spectrometric data was minimized by modifying isotopic fractional abundances of the 
atoms involved. FIRMS was used to calculate the isotope abundances of molecules of 17 




1‰, for 13C compared with IRMS in a fraction of the time. FIRMS also produced 
excellent accuracy for 13C values with an absolute error of less than 1.6‰ compared to 
IRMS. It was also successfully coupled with LCMSMS to analyze 13C for DIMPA, 
caffeine and acetylsalicylic acid with standard deviation of less than 1‰ and accuracies 
within 1‰ compared to IRMS. The bivariate plot of FIRMS versus IRMS showed an 
excellent R2 of 0.992 with a slope of 1, validating the new technique as an accurate isotope 
ratio measurement technique. FIRMS offers several advantages over other methods of IR 
determination, and may ultimately become the preferred method for determination of IRs. 
The disciplines that will benefit from development of FIRMS include: 1) forensic science, 
2) environmental chemistry, 3) geology, 4) geochemistry, 5) cosmochemistry, 6) food 
sciences, 7) earth science, and 8) pharmaceutical science. FIRMS will make IR analysis 
more widely available, fast and less expensive for scientists to conduct research in these 
fields, as well as train new graduate students for future scientific research and development 




















CHAPTER 1: Introduction 
 
1.1 Motivation and Objective 
 
Counterfeiting is a threat to every aspect of the world economy, including 
innovation, technology, and industrial relations, such as production and manufacturing. 
Commonly used materials and products that require incredible input in research, 
development and marketing are frequently targeted.1 Counterfeiting has grown into 
enterprise  primarily because of weak regulation in many countries. Research shows that 
the regulations target the supply of fake goods and do not address the high consumer 
demand for cheap and affordable products. 2 3 
Thus, tools and mechanisms must be put in place to fight the supply of 
counterfeited products. For example, developing a fast and reliable technology capable of 
tracing the source of counterfeit products made from organic materials can be used to 
determine the authenticity of goods. Tracing organic products is possible because 
chemical compounds are composed of atoms, most of which have stable isotopic forms.4-
6 Using isotope tracing methods 7-9 and carbon dating10 products can be authenticated.  
Isotope ratios (IRs) are used to trace the history of compounds and a measure of 
the ratio abundance of light isotopes versus heavy isotopes of an element, such as 1H/2H, 
12C/13C, 14N/15N, 35Cl/37Cl and 79Br/81Br. These ratios are largely quite consistent, with 
the original isotope frequencies of each terrestrial element fixed upon the formation of 
the earth.11 But, experimental observations show changes in relative isotope abundances 
occur over time due to natural phenomena, 11 including radioactivity,12-13 anthropogenic 
activities,14 cosmic ray interaction,15-17 and fractionation.11 Radioactive decay affects IRs 





which occasionally enter the earth’s magnetic field, may result in neutron capture, 
thereby changing the isotope ratios of certain atoms. 17-19 For example, 36Cl formation 
occurs when 35Cl captures neutrons produced in muon capture and muon-induced 
photodisintegration reactions. 20 Anthropogenic activities, such as industrial nuclear 
reactions and mining affects IRs by enriching some isotopes.21 Fractionation is a process 
where different isotopes of an element produce slightly different chemical and physical 
properties, resulting in changes in isotope ratios as molecules undergo certain chemical 
and physical processes.22 For example, in biological processes, some factors, such as 
genetics, affect the fractionation process as plants utilize CO2 for photosynthesis. Plant 
types follow different photosynthesis pathways and processes that result in unique IRs. 
These ratios from each plant food source become integrated into an animal’s biology 
based on their diets. Table 1.1 shows the photosynthetic cycle and 13C values for 
different plant types (i.e.,  is a measure of 13C/12C compared to a reference material and 
represented as a “per mil” or parts per thousand, denoted as ‰).  
Table 1.1. Photosynthesis cycle and 13C values of different plants 
Plant type Photosynthesis 
cycle 
Examples 13C values range (‰) 
C3 (dicotyledonous) Calvin-Benson Wheat and beans -23 to -22
23 
C4 (monocotyledonous) Hatch-Slack Millet and corn -8 to -20 
23-24 




-10 to -3411 
 
  The change in IRs as a molecule undergoes certain chemical and physical 





chemical compound. For example, animals from North America are distinguished from 
European animals because of different 13C values. European meat products have lower 
levels of 13C because they feed on C3 plants, while North Americans have higher 
13C 
values because they feed on C4 plants.
11 
 Although IRs are extremely important in a number of areas, it continues to be 
very difficult and costly to determine IRs from currently available techniques. Thus, the 
objective of this study was to develop a laboratory-based analytical technique, known as 
Fast Isotope Ratio Mass Spectrometry (FIRMS), as a next-generation analysis method. 
FIRMS uses tandem mass spectrometry data and a nonlinear mathematical model 
describing the probability of compound fragmentation to extract IRs of locations of 
individual atoms or groups of atoms within a molecule. It is a rapid, accurate, sensitive, 
robust, and more comprehensive method that evaluates IRs with promise to definitively 
identify the source/history of the chemical components of the material.  
1.2 Importance of isotope ratios (IRs) 
 Isotope ratios (IRs) have remained a significant area of research interest for many 
decades as documented by the number of scientific publications. Applications of IRs 
have grown over time in areas that include forensic science, food and drugs analysis, diet, 
biochemistry and metabolism, doping investigations, and environmental pollution.11 
Figure 1.1 shows the number of publications based on isotope research work from the 
year 1950 to 2017. The figure shows that the number of publications with IRs as a subject 






Figure 1.1. Shows the number of publications per decades for IRs research from the year 
1950 to 2017 obtained from Google Scholar on May 4, 2017. 
 
 
In forensic science, IRs have been used to identify the source of counterfeit 
materials by linking the evidence to a particular geographical place or a person.25 In the 
past, these materials have included: explosives, ignitable liquids,25 illicit drugs,25-26 
prehistoric evidence,27 and nuclear arms.28 For food, beverage, and water safety IRs are 
used to identify the origin of products,29-31 confirm if components indicated by food and 
beverage manufacturer agree with the actual content of the product, and to analyze 
pollutants in drinking water.11 IRs are also used to establish the dietary pattern, metabolic 
class, and movement of domestic animals such as cattle.11 In suspected athlete doping 
activities, IRs are used to analyze performance enhancing compounds that are thought to 
be synthetic. For example, gas-chromatography IRMS (GC-IRMS) has been used to 
analyze carbon isotope ratios of nandrolone (NAD). NAD is an endogenous steroid 
hormone metabolite used by some athletes, or in racehorses to enhance performance.32 




































endogenous and exogenous concentrations of synthetic steroid 19-norandrosterone, a 
metabolite of 19-nortestosterone by using isotopically labeled standards to compare 
isotopic carbon ratios and determine the origin of urinary norandrosterone.33 
Environmental pollution agencies (e.g., U.S. EPA) employ GC-IRMS methods for 
pollution control and health safety to analyze carbon isotopes of pollutants, such as 
polycyclic aromatic hydrocarbons (PAHs), to identify the source of pollutants.11, 34 
 In recent years, IRs have been expanded to include identification of counterfeit 
drugs. Counterfeiting medicine has led to a significant number of fatalities. According to 
World Health Organization (WHO), substandard, spurious, falsely labeled, falsified and 
counterfeit (SSFFC) products have continued to undermine the treatment of deadly 
diseases such as malaria and tuberculosis. WHO has reported that counterfeit drugs 
include over 920 medical products, such as therapeutics, and generic medicines, 
antimalarials and antibiotics as the most counterfeited drugs globally.35 
Counterfeit drugs disproportionately exist in illegal markets (unregulated 
pharmacies, clinics, and hospitals) and online. Their production is done under unhygienic 
conditions by unqualified workers. These false medicines might contain nonmalignant 
ingredients such as flour, sugar, and pollen, instead of active pharmaceutical ingredients 
(API); may contain lower doses of the API than the authentic drug; may contain 
components, such as aspirin that are capable of feigning treatment; or an entirely illegal 
API that can be poisonous.35 
Falsifying products is a practice that has thrived because of the limitations of 
current technologies as well as weak laws. Given the complexity and effects of the 





technology that allows rapid and robust determination of IRs in raw materials and 
products made from natural compounds. Organic compounds are ubiquitous in essentially 
all products that could be counterfeited. Additionally, this technology could be extended 
to analyze organic pollutants and biological samples collected from crime scenes for 
forensic analysis and other applications. If the technology developed can determine the 
source of a chemical compound, it will give organizations such as law enforcement the 
ability to investigate and arrest criminal entities involved in manufacturing and selling of 
illegal medicine, food and other consumer products. 
1.3 Effects of counterfeit medicines 
1.3.1 Public health 
Countries with a weak regulatory system for imported and locally produced 
medicine often experience public health crises because of SSFFC products. In such 
countries, a safe and reliable quality medicine supply for health care is almost non-
existent.36 Thus, these countries experience a high level of untreated disease, deaths and 
treatment failures based on counterfeit medicines.37 
A significant number of fatalities have been recorded over the years as a result of 
SSFFC medicine. For example, in 2008 and 2009, 84 Nigerian children died from acute 
kidney failure due to presence of diethylene glycol  (an active ingredient in antifreeze) in 
a counterfeited teething syrup.38-39 The same diethylene glycol was sold to a European 
company as pharmaceutical-grade glycerin by a Chinese chemical manufacturer. It  killed 
219 people from acute kidney failure in Panama in 2007.40 In the Panama case, the 





cough syrup were contaminated, as reported by the Panama Ministry of Health and 
WHO.41 
Another example of the effect of falsified medicine is the rise of untreated 
diseases that progress over time, eventually leading to deaths. There is evidence of such 
cases documented from parts of the world where it is too costly to have the technology to 
verify and authenticate or evaluate the quality of medicine. For example, in Ghana 
researchers found that 89% of the uterotonic drugs oxytocin and ergometrine did not 
meet the required standards by British Pharmacopoeia specification, and 2% of the 
medicines were expired. In this case, only 9% of the drugs were found effective in curing 
the intended diseases.42 Hemorrhage, a treatable condition using uterotonic medicine, is 
the main cause of a high maternal mortality ratio in Ghana estimated to be 350 per 
100000 live births.43-44 That means hemorrhage accounts for an estimated 17 to 22% of 
maternal deaths in Ghana. 45 
 Treatment of chronic diseases such as diabetes has increasingly become a serious 
challenge to health institutions because cheap counterfeit drugs have flooded the health 
industry affecting health quality. For example, in China, a fake version of the diabetes 
drug, glyburide, was found to have six times the pharmacopeial standard dose and 
resulted in the death of two patients.46 Fifty percent of popular brands of the oral diabetes 
drug metformin failed several pharmacopeial tests of bioequivalence, thus directly or 
indirectly affecting 80% of 347 million diabetic patients who live in developing 
countries.47-48  
Antibiotics, which are the most important medication for infectious diseases 





45% of the 771 counterfeit cases documented and reported by WHO.49 Therefore, a large 
number of antibiotics, such as penicillin and amoxicillin commonly used for treating 
bacterial infections, including scarlet fever, respiratory and urinary tract infections, and 
pneumonia, are counterfeit.37 It is worth noting that bacterial Pneumonia, which is caused 
by the pathogen Streptococcus pneumoniae, accounts for 12% child deaths globally.50 
Lastly, counterfeit drugs can also lead to catastrophic treatment failures, such as 
bacteria, and virus drug resistance, based on incorrect API concentration. Bacteria 
resistance is problematic to health research plans, health systems, health care providers 
and people seeking medical care. Such resistance can jeopardize decades of research and 
development of medicine.  There are already such cases reported by healthcare providers 
and health institutions. For example,  many tuberculosis drugs have been reported to be 
ineffective for treatment because Mycobacterium tuberculosis, the bacterium causing 
tuberculosis, has gradually become drug resistant.51 This bacterium accounts for nearly 
6% of global drug-resistant infections.52 Often, these infections are complex and 
challenging to treat, and are responsible for multiple deaths around the globe. 53-59  
1.3.2 Economic and social impact of counterfeit drugs 
 The cost of manufacturing drugs, from research to production, is currently 
estimated to be more than $1.3 billion.60  Figure 1.2 shows the estimated increase in drug 
development cost since 1975. Since most drug research is tax funded by citizens, the cost 
is often transferred to consumers. For many families in middle-income and poor 
economic status, increasing drug prices create financial difficulties. In many cases, 





bacteria and viruses develop drug resistance, it renders drugs ineffective that cost billions 
of dollars to produce. This drives the cost of developing drugs higher.62-64 
The high cost of developing medicine creates a situation where these treatments 
become too expensive to afford, and also drives health insurance costs higher.62 This can 
lead to corruption in health institutions, in which only those who can afford it have access 
to the best medicines.61 Organized crime and terrorist activities can also be funded by 
counterfeit medicines.65.  All these cases are not good for the economy and have a 
negative impact on the social welfare of communities.  
 
Figure 1.2. The increase in the cost of drug development since 1975. 
 
Overall, counterfeit pharmaceuticals can lead to mass poisoning, disease 




























drug costs, loss of confidence in health systems, health care providers, medicine and 
national and international regulatory agencies, and funding of criminal and corrupt 
enterprises. 
1.4 Overview of Techniques for Detecting SSFFC 
The impact of SSFFC on health care, social life and economy of many countries 
around the world is severe. Thus, there is a critical need to develop technologies to 
examine and analyze counterfeit products. Visual inspection can sometimes identify 
counterfeit goods, such as currencies, relevant documents, antiques, and  medicines.65 
The conventional optical technologies available for detecting SSFFC from the WHO 
Checklist,66 are multidimensional atomic force microscopy,67 GPHF-MiniLab68-69 and 
Counter Detection Device (CD-3).70-71 The WHO checklist is freely available for 
healthcare workers including pharmacy and laboratory technicians with minimum 
training requirements.66 Atomic microscopy authenticates products by reading the 
molecular watermarks imprinted on products. It is expensive, requires a climate-
controlled environment and a well-trained scientist to operate and maintain it. 67 Visual 
inspection in many cases is a first step in authenticating materials, and other additional 
advanced technologies are required to identify SSFFC because many counterfeiters have 
already developed technology that can evade hi-tech visual inspections.64 The advanced 
technologies needed in addition to visual inspection include portable technologies and 
analytical laboratory techniques.  
 Large instruments cannot be utilized in certain areas, such as remote locations, 
ports, and pharmacies. Thus, mobile devices for detecting counterfeit products are 





Resonance (NQR),72-73 Raman,74-75 near-infrared (NIR) light spectroscopy,76-77 
chromatography techniques,78 Fast Chemical Identification System (FCIS),79 and GPHF-
MiniLab.68-69  
These techniques have several advantages because they are cheap technologies 
(e.g., chromatography techniques that include TLC Speedy Apparatus, and CD-3) except 
Raman and NIR portable devices. In all cases, they do not require sample preparation, 
they are portable, and relatively fast in analyzing samples. Additionally, they do not need 
extra supplies and call for minimal training time. However, CD-3, Raman, and NIR 
portable devices have a limitation because they depend on the use of reference libraries of 
pharmaceuticals to identify counterfeit products.80 Dependence on reference libraries 
causes problems especially if malicious individuals have access to the database. 80They 
are also incapable of analyzing complex matrices that are uniquely identical such as 
enantiomer mixtures, or the same compounds produced from two different sources. Thus, 
complex forms and analysis of the same compounds from various sources require 




















CHAPTER 2: Currently available IR analysis methods 
 
2.1 Analytical laboratory technology for IRs analysis 
There are several techniques available for evaluating IRs. Isotope Ratio Mass 
Spectrometry (IRMS),11 Nuclear Magnetic Resonance (NMR) Spectroscopy,81Infrared 
Laser Absorption Spectroscopy (ILAS) and Cavity-Ring Down Spectroscopy (CRDS). 82-
83 CRDS, IRMS and NMR are the most commonly used for counterfeit detection. 
2.1.1 Infrared Laser Absorption Spectroscopy (ILAS) 
ILAS was developed as an alternative to the established IRMS for the 
measurement of IRs of atmospheric CO2. It uses the mid-IR spectral region that allows 
measurements of IRs with high-sensitivity due to rotational-vibrational bands of strong 
and important vibrations that affect CO2 in the region. It also uses fast scan rate to 
acquire spectra that increases sensitivity; for example, 1400 spectra / s at 1.4kHz for IRs 
calculations.84-90 
 It has an advantage over IRMS because mass isotopologues are eliminated based 
on distinctive absorptions by of trace gas molecules. ILAS is also cheap, consumes less 
power and benchtop space, and does not require high purifications and highly purified 
gases. However, it is not efficient for batch analysis in a laboratory set up except for 
medical detection and diagnosis of infections such as H. pylori through human breath. 
But it requires large amounts of CaCO3 for that type of analysis which is unfeasible in 
most earth science research.87, 90-91 
ILAS was recently improved using a more sensitive tunable infrared laser direct 
absorption spectroscopy (TILDAS) shown in Figure 2.1. It uses a quantum cascade laser 






12C18O16O, 12C17O16O and 13C16O2) shown in Figure 2.2. The miniaturized absorption cell 
is vacuum tight, and allows CO2 to flow into a pre-evacuated cell and then be separated at 
a low pressure and detected by a thermoelectrically cooled photovoltaic detector. For 
each isotopologue the output is calculated using nonlinear least-squares fitting of the 
absorption spectrum and produces a peak area that is used to find a ratio with other peaks. 
The calibration is done against CO2 derived from standard carbonates with known stable 
IRs.92 
 
Figure 2.1. A schematic diagram of isotope ratio measurement system. It consists of a 
CaCO3 reaction unit, CO2 purification unit, and tunable infrared laser absorption 
spectroscopy (TILDAS) system. TILDA, shown highlighted in orange has multipass cell 















Figure 2.2. CO2 absorption spectrum acquired by TILDAS technique with a 36 m 
absorption path at 10 Torr (1333 Pa) total pressure. The measured spectrum is marked 
green with a fitting marked as black. The black dotted line represents the fit background. 
The horizontal axis shows the quantum cascade laser (QCL) that scans the laser 
frequency range by means of 800 channels at 1.4kHz.92 
 
2.1.2 Nuclear Magnetic Resonance (NMR) Spectroscopy  
NMR methods have several advantages that are fundamental to their applications. 
They are  non-destructive.93 They can be faster than chromatographic techniques.94 SS-
NMR spectroscopy is capable of analyzing both active pharmaceutical ingredients (API) 
95-96 and the excipients,97-99 and is well-suited for the study of polymorphism100 because it 
can differentiate conformational polymorphism from stereochemical differences.96 When 
compared to powder X-ray diffraction (P-XRD), NMR  is capable of analyzing chemical 
compounds in the amorphous state101-102 of different patterns of generic drugs in the 
spectrum81 103 thus widely applied in the analysis of counterfeit e.g., analysis of acetyl 
vardenafil (i.e., API in viagra) and vardenafil shown in Figure 2.3. But NMR does not 





low intensity that might be suppressed or overlapped by signals from excipients96, 104 93 



























Figure 2.3. The structure of acetyl vardenafil (A) and vardenafil (B). 
 
 Unlike general NMR used for structural analysis of compounds, Site-specific 
Natural Isotope Fractionation NMR (SNIF-NMR) is used to determine hydrogen (2H 
SNIF-NMR) and carbon (13C SNIF-NMR) isotope ratios of organic compounds with 
excellent accuracy. SNIF-NMR has the major advantage of measuring the isotope ratios 
at individual locations in a molecule without converting compounds to gaseous products 





quantitative adiabatic composite refocusing 13C NMR pulse sequence for site-specific 
isotopic measurements by determining 13C/12C site-specific isotope ratios.105-107  
 SNIF-NMR is built on the principle of natural isotopic fractionation and is 
regularly used to authenticate food. For SNIF-NMR function the molecules used must be 
purified or pure. The method involves, for example, the fermentation of juice, 
quantitative extraction of alcohol (e.g., ethanol) by the process of distillation, preparation 
of samples for NRM analysis, NRM acquisition and interpretation of results.108-109 
 For the interpretation of the site-specific isotope ratio, 𝑅𝑖, of a given molecular 
site, 𝑖, is defined as (𝐷 𝐻)⁄
𝑖
= 𝐷𝑖 𝐻𝑖⁄  where 𝐷𝑖 is the number of deuterium atoms at site 𝑖 
and represents the number of isotopomers mono-deuterated at site 𝑖. 𝐻𝑖, is the total 
number of hydrogen atoms of type 𝑖, which is equivalent to 𝑃𝑖𝑁𝐻 where 𝑃𝑖 is the number 
of equal positions at site 𝑖 and 𝑁𝐻 the number of fully protonated molecules.
110  
 Another important parameter that is used to quantify experimental data is 𝑅𝑖/𝑗also 
defined as 𝑅𝑖/𝑗 = 𝐹𝑗𝑆𝑖 𝑆𝑗⁄  where S is the intensity of signal 𝑖 or 𝑗 (i.e., the area of the 
NMR signal). 𝑅𝑖/𝑗 represents the number of heavy isotopes at site 𝑖 in circumstances 
where site 𝑗is randomly given its known stoichiometric number of atoms, 𝐹𝑗. Using this 
information, SNIF can access directly and simultaneously the hydrogen isotope ratios, 
(D/H) relative to different positions, 𝑖, in a given molecule.110  
 Overall, NMR methods developed to analyze 13C/12C and 2H/1H isotope ratios for 
specific atomic sites in organic compounds and to study isotope ratio patterns of complex 
organic molecules have numerous applications.106, 111-114 They are used to analyze and 
authenticate food such as wine, sugar, fruit juices and olive oil.115 It has also been 





investigations.116 However, technical limitations of NMR include relatively low precision 
(~1 per mil), large samples size requirement (mg or greater), long integration times, and 
low sensitivity.114  
2.1.3 Cavity Ring-Down Spectroscopy (CRDS) 
 CRDS is an efficient technique for determining 13C/12C117 ,16O/17O and  2H/1H118 
IRs based on the relative absorption lines of carbon dioxide, water vapor118-119 and 
methane.118 It operates by tuning a laser source to the spectrophotometric absorption lines 
of interest and measuring the decay rate of the light intensity, 120 which allows 
determination of the relative abundance of isotopes of interest. 
CRDS has the advantages of accurate quantitative measurements, speed, and 
simplicity. However, it has several limitations, since it suffers from low selectivity and 
low sensitivity. Combustion of compounds is necessary for CRDS, leading to loss of 
structural information which allows for determination of the aggregate isotopes for one 
element at a time. It is prone to inconsistencies because of the delicate mirrored surfaces 
necessary to perform the technique. CRDS is commonly used to determine IRs of only 
carbon, hydrogen, and oxygen. 120 Despite the fact that nitrogen and sulfur isotopes have 
been analyzed via optical techniques they are rarely analyzed using CRDS for most 
organic compounds. 118-119 
2.1.4 Isotope Ratios Mass Spectrometry (IRMS) 
2.1.4.1 Background 
 Forensic, geological and environmental scientists widely apply IRMS for tracing 
origin/history of materials. Many IRMS applications have emerged in the past four 





IRMS can be traced back to 1918 by A. J. Dempster.121-122 Alfred Nier built the original 
version of the IRMS in 1936 that featured a 180° magnetic sector field analyzer. It was 
used to determine significant isotopic data122-123 in wood, oil and other biogenic materials 
for 13C depletion. Later in 1947, Nier introduced a modern day IRMS that featured 
multiple collectors and a magnetic sector mass filter.122-124 IRMS technique became a 
standard instrument for the geosciences and other related fields almost immediately after 
World War II. By 1950, IRMS had been used in studies of systematic variation of 
13C/12C, and fundamental depletion of 13C in organic materials.122, 124 Modern IRMSs 
(schematic diagram shown in Figure 2.4) retain most of the original features, but a novel 
interface, called continuous flow interface, was developed derived from the principle of 
viscous flow of carrier gas continuously spiking bands of sample gas into the ion source. 
The continuous flow method enabled online coupling of different analytical techniques 
with IRMS. With this coupling ability, sample signals are transient and appear as peaks. 
A special algorithm has since been created to calculate isotope ratios from signal/peaks 
accurately.122, 125 The continuous flow interface has also eliminated analytical errors due 






Figure 2.4. Schematic diagram of modern-day IRMS.11 
 
 The first interfaced continuous-flow isotope ratio mass spectrometry (CF-IRMS) 
unit was introduced by Preston and McMillan when they coupled an elemental analyzer 
to an IRMS via a variable leak.127 Among other improvements was the ability of IRMS to 
analyze 15N labeled compounds, introduced in 1978.128 Around 1984, IRMS was 
integrated with gas chromatography (GC) via a combustion unit for GC-C-IRMS. This 
eventually allowed analysis of stable isotope ratios at natural abundance.122, 129 Currently, 
two types of IRMS are available, the Elemental Analyzer (EA-IRMS), used for analyzing 
C and N, and the High-Temperature Thermal Conversion EA-IRMS (TC-EA-IRMS) 
used for analyzing H and O isotopes.11 
 





 In EA-IRMS, shown in Figure 2.5, a sample is initially subjected to elemental 
analysis by being combusted at 900C to produce N2, NO, NO2, H2O and CO2 in the 
presence of an oxidant, such as copper or chromium oxide. A reduction process follows 
in a stream of helium before determination of the relative abundance of isotopes in the 
sample via IRMS. On the other hand, the analysis process in TC-EA-IRMS shown in 
Figure 2.6 involves the thermal conversion of sample in a reactor at elevated 
temperatures (usually > 1000C) in the presence of reactive C in a continuous flow of 
He.130 
 
Figure 2.5. Schematic diagram of an EA-IRMS for the analysis of 13C and 15N.131 
 
 
 In both IRMS techniques, a sample is quantitatively converted into a gas (with 
approximately identical molecular weight) and chromatographically separated by a GC 
before introduction into the ion source of the IRMS. The gaseous sample undergoes 









e.g., 10 keV relative to the ground passing through an electrostatic analyzer (ESA) before 
entering the magnetic field. The ion beam then goes through the rotation and focusing 
quadrupole lenses before inflowing to the magnetic sector electromagnet controlled by 
feedback from a field probe. After the ion beam exits the magnet, they pass through a 
second focusing quadrupole before reaching the detector array.114 When the ions reach 
the mass analyzer, they encounter a multi-collector array containing eight pairs of 
detectors, each pair consisting of an electron multiplier and Faraday cup adjacent to one 
another. The electric 
 
 
Figure 2.6. Schematic diagram of TC/EA-IRMS for the analysis of 2H and 18O.131 
currents produced by ion beam are registered in Faraday cups and recorded as signals.114 
Then, IRs are measured by monitoring ion current intensity at selected m/z ratios. For 





of [12C16O18O] + and [12C16O16O] + ion, respectively.130 The IR is reported as  (parts per 
mil) calculated using Equation 1.11, 114  
  𝜕 = (
𝑅𝑠𝑎𝑚𝑝𝑙𝑒
𝑅𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
− 1) 𝑥 1000      (1) 
where  is the value of the ratio of sample and standard measured, Rsample is the ratio of 
the isotope of samples, and Rstandard is the ratio of the isotope of the standard.
11 
2.1.4.3 Advantages and disadvantages of IRMS 
 In general, IRMS is considered the most accurate, precise and reliable method for 
determining IRs. It is exceptional for analysis of total IRs of specific elements in 
compounds. Additionally, it has several significant strengths: 1) its Nier-type electron 
impact (EI) ion source can generate excellent currents (nA to A) and stable ion beams; 
2) its multiplier-collector arrays allow very precise measurements of small relative 
differences in isotopic compositions; 3) the dual viscous-bleed inlet system used on many 
gas source IRMS allows fast comparison of sample and standard under identical 
conditions, producing excellent accuracy.114, 136-139  
Overall, IRMS is exceptional for determining aggregate IRs of compounds. 
However, the current IRMSs also have limitations that affect the extent to which they 
measure IRs. IRMS analytes must be gases mostly of low molecular weight with a 
significantly high vapor pressure at standard room temperature for delivery to the EI ion 
source with a carrier gas. IRMSs detect ions using only Faraday cups, which are good for 
linearity but have significant background currents (~fA) which increases detection 
limits.128, 140-141 IRMSs also have low mass resolving power (~200), significantly lower 
than most complex thermal, plasma and secondary ion mass spectrometers (~10,000) 





beam). The low resolution means that IRMSs are incapable of differentiating analyte ions 
from isobaric interferences, including contaminant gases. For example, H16O, and 13CH4 
at 17 amu, or 12C16O2
2H+ and 13C16O2H
+ at 45 amu, and the isotopologues of the same gas 
that share cardinal mass e.g., 13CH4 and 
12CH3D; a phenomenon defined as isotopic 
isobars. Thus, IRMSs are mostly used to measure specific analytes that can be easily 
purified, with less significant isobaric interferences and ubiquitous vacuum contaminants 
with a simple stoichiometry that ion-correction schemes can deconvolve, at least for 
some of their isotopic isobars.114  Compounds analyzed by IRMS must be highly purified, 
otherwise impurities from solvents, and other contaminants might affect IRs obtained. 
For example, during isolation of compounds from plants or drugs, achieving adequate 
purification (i.e., close to 100%) is very difficult. IRMS is a very sophisticated technique 
that is difficult to implement, especially for certain elements. For example, Br and Cl IR 
measurements are quite involved, since they require conversion of  Br and Cl compounds 
to other products, such as HCl142 which requires additional sample preparation methods, 
such as SPME.143 Also, IRMS methods lead to loss of all structural information11 such 
that only aggregate isotope ratios are available at the end of analysis due to combustion 
of compounds to produce gases, such as CO2, N2, H2O or NO2. Lastly, IRMS is limited to 
analysis of one element at a time. 
Collectively, the existing IRs analysis techniques and methods have played 
important roles towards the advancement of isotope research and studies.  However, 
given their limitations, there is a critical need for a new method for IRs analysis which is 
fast, sensitive, selective, inexpensive and relatively easy to implement. It should be able 





have the ability to determine IRs for all elements simultaneously. The method should 


























CHAPTER 3: Fast Isotope Ratios Mass Spectrometry (FIRMS) 
3.1 Introduction to FIRMS 
 We developed FIRMS as an alternative method for IR analysis due to the 
limitations of IRMS. It is a novel, unique and potentially transformative technology that 
accurately and precisely predicts isotope ratios for elements in a compound in a fraction 
of the time of other methods. It calculates separate isotope ratios for individual atom 
locations or portions of the molecule. FIRMS has the potential to also calculate IRs that 
are difficult to determine (e.g., S, Cl, and Br), and to determine the IRs of all elements in 
a molecule simultaneously. It is the first IR analysis technique to use experimental data 
obtained via various tandem MS techniques to determine IRs and is self-reproducing. 
Unlike IRMS, which relies on high-resolution MS with a magnetic sector as the primary 
mass analyzer, FIRMS can be coupled with multiple types of mass spectrometers. 
The tandem MS technologies amenable for FIRMS include ion-trap, quadrupole 
ion-trap, triple quadrupole and quadrupole time-of-flight. The experimental data collected 
via these techniques are analyzed using a non-linear mathematical model describing the 
probability of compound fragmentation to extract IRs of locations of individual atoms or 
group of atoms within the molecule. Mathematically, the model is of the form c(𝒙)⃑⃑⃑⃑ =
|𝒇(?⃑? )𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 − 𝒇(?⃑? )𝑬𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍|: Where 𝒄(𝒙)⃑⃑⃑⃑⃑⃑ ∶  ℝ
𝒏 → ℝ are composite or multi-
objective functions (MOF) mapped on a vector space (given n is an integer) with 𝛀 ⊆
 ℝ𝒏 as the feasible region, subject to constraints. The isotope abundance fractions are the 
variables, 𝒇 𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 is a polynomial function of n
th order mapped in a vector space, and 
𝑓𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 is a constant calculated from the experimental data. FIRMS’s non-linear 





𝒄(𝒙)⃑⃑⃑⃑⃑⃑  ,  a composite or sum of several single objective functions (SOF) multiplied by 
weighting coefficients.  
3.2 Development of FIRMS 
3.2.1 Isotope Ratios (IRs) 
 The evaluation of IRs can help probe the history and source of molecules. For 
example, the fixed average global isotope abundances of tertbutyl chloride (C4H9Cl)  are 
98.93% 12C, and 1.07% 13C.144 However, the isotope ratio of each element of a group of 
related tertbutyl chloride molecules is unique and can act like a fingerprint.11 Moreover, 
the IR of each atom location can reveal further information to determine the history of a 
group of tertbutyl chloride molecules.  The IR information can be obtained from mass 
spectra using various tandem MS techniques. 
3.2.2 Transformation of mass spectra for FIRMS  
 Fragmentation of a molecule during mass spectrometric analysis produces signals 
that correlate to the number of charged molecules of a particular mass-to-charge ratio. 
Thus, mass spectral data for a given fragment can be associated to isotope ratios. For 
example, the typical isotope ratio of 37Cl/35Cl, 0.35, is commonly used to evaluate mass 
fragments for the presence of chlorine. Figure 3.1A shows a simplified mass spectrum of 
tertbutyl chloride. The inset shows a close up of the m/z ratios associated with the 
isotopes of the molecular ion (i.e., 77, 78 and 79 m/z). The ratio of the abundance of the 
79/77 m/z ions, approximately 0.35, supports the presence of chlorine in the molecular 
ion. When evaluating the entire mass spectrum of a molecule, the ratio between separate 
fragments is not solely due to differences in isotope ratios. It is also due to a number of 





for individual fragments. Because most of these factors cannot be accurately estimated, 
isotope ratios cannot be calculated by this type of mass spectrum alone (i.e., the mass 
spectrum produced from fragmentation and mass filtering once each, referred to as a 
precursor ion scan when using tandem mass spectrometry). Fortunately, tandem mass 
spectrometry offers the ability to fragment and mass filter molecules twice, which allows 
the ability to gather information as to the fragmentation efficiency and the sensitivity of 
fragments relative to each other under a particular set of conditions. When the 
fragmentation and sensitivity are consistent, the product scans of isotopes (e.g., 77, 78, 
and 79 m/z; Figures 3.1B-D, respectively) should only differ based on the isotopic 
makeup of the molecular ion or fragment. Therefore, a series of mathematical equations 
can be derived that relates the relative ion abundances to the isotope ratios. This is done 
using the product ion scan of a molecular ion or a fragment (e.g., 77 m/z in Figure 3.1B) 
as a “template” and relating the differences in the heavier isomer fragmentation to the 
isotope ratios (e.g., 78 and 79 m/z; Figure 3.1C and 3.1D, respectively).  
The mathematical equations that define the FIRMS technique are derived by first 
transforming the product ions of the base mass spectrum into fractions of the total 
abundance via Equation 2,  
     𝛼𝑖 =
𝛾𝑖
𝑇𝑀
,     (2) 
where 𝛼𝑖  is the frequency of occurrence of the fragment of interest 𝑖, 𝛾𝑖 is the abundance 
of fragment 𝑖, and 𝑇𝑀 is the sum of abundances of all fragments for the mass of interest, 
M. For example, when evaluating 77 m/z (Figure 3.1B) for tertbutyl chloride, 𝛼39 is 
calculated by Equation 3,  
     𝛼39 =
𝛾39
𝑇77






Figure 3.1. Simplified tandem mass spectral data for t-butyl chloride (2-chloro-2-
methylpropane) obtained from a GC-MS-MS. A) Precursor ion scan (Q3-scan) of t-butyl 
chloride with the molecular ion region magnified in the inset. B) Product ion scan of m/z 
= 77. C) Product ion scan of m/z = 78. D) Product ion scan of m/z = 79. The differences 
between the product ion scan of the base mass (m/z = 77; B) and the heavier stable 
isotopes (m/z = 78 and 79; C and D, respectively) can be attributed to the isotope ratios of 
the atoms involved. The difference between the precursor ion scan (A) and the product 
ion scan of 77 (B) is due to the differences in ionization processes responsible for 
fragmentation.  
 
The  values are the “template” to which all the heavier isotope fragmentations are 
related. The same transformation process is then performed on the heavier stable isotope 
product ion scans, with a mass of 𝑚 and the frequency of occurrence now represented by 





     𝜇𝑖,𝑚 =
𝛾𝑖,𝑚
𝑇𝑚
  .      (4) 
3.2.3 Isotope ratio calculation 
 Fragmentation patterns observed in mass spectra occur when a molecule 
fragments into smaller pieces. The fragmentation patterns of each heavier stable isotope 
(i.e., the 𝜇s) can be related by the base mass (M) fragmentation pattern (i.e., the 𝛼s) and 
the isotope ratios of the atoms which make up the heavier isotopes. Therefore, 𝜇𝑖,𝑚 can 
also be written in terms of Equation 5, with each isotope ratio product series calculated 
by Equation 6. 
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𝑒=1      (6) 
where 𝜎𝑗,𝑖,𝑚 is the isotope ratio product series function corresponding to the precursor ion 
of interest (𝑚), where 𝑥 is the number of possible molecular ions or fragments, with mass 
m, potentially contributing to the mass fragment of interest (𝑖). The 𝜎𝑘,𝑚 is the isotope 
ratio product series function corresponding to all possible isotopes with mass 𝑚, where 𝑦 
is the number of possible molecular ions/fragments with the m/z of the precursor ion of 
interest (𝑚). 𝑓𝑒,𝑎 is the isotope ratio of an individual atom, a, of element, e, in the 
fragment of interest (𝑖), fragmented from the precursor ion of interest (𝑚), with E as the 
total number of elements and A as the total number of atoms of element e associated with 
the precursor ion of interest (𝑚).   
 Equations 5 and 6 are original and can be used to predict the intensities of the 
product ions from the stable isotopes of interest, typically M+1, M+2, etc. For example, 





Equation 7 and 8, respectively, and the isotope ratio product series function for 
13C12C2
1H6















  (8) 
 𝜎13𝐶12𝐶21𝐻635𝐶𝑙,40,78 = 𝑓13𝐶𝑓12𝐶
2 𝑓1𝐻
6 𝑓35𝐶𝑙    (9) 
The coefficients 3 and 6 in Equations 7 and 8 represent the number of possible isotopic 
combinations of atoms involved which would lead to a fragment with a mass of 78 m/z 
and product ion of 39 m/z. Equations 7 and 8 are actually a simplification of the FIRMS 
model in which the isotope ratios of each element are calculated in aggregate (i.e., only 
one 13C/12C ratio is calculated for the entire molecule). In the full FIRMS model, the 
isotope ratio of each atom location is calculated individually. This is important for 
accuracy of the calculated isotope ratios since, in some situations, only specific atoms 
may contribute to certain fragments.  
For very simple molecules, explicit solutions may be found if another independent 
equation is available. Fortunately, another equation that relates the total abundance of the 
base mass to the abundance of the heavier isotope fragment or molecular ion can be 
written as Equation 10, with 𝑇𝑐,𝑚 and  𝑇𝑐,𝑀 experimentally available by adding all the 
















where 𝑅𝑚/𝑀 is the ratio of the sum of 𝜎s that make up the masses 𝑚 and 𝑀, and 𝑧 is the 
number of possible molecular ions or fragments with the m/z of the base mass of interest 
(𝑀).  
3.2.4 FIRMS IRs theorem 
 It is important that the general proposition of IR calculations by FIRMS be 
reasonably proved with a logical demonstration that they will predict correct IRs. If the 
predicted IRs model is accurate, FIRMS functions will accurately calculate isotope 
abundances with very good accuracy. The proof of FIRMS IRs theorem must follow the 
logical true statement that says: 
For the isotope ratio calculations, the sum of FIRMS 𝜇s must be one, because the 
sum of experimental µ(s) is one. 
To test this statement, let us consider Equation 4, which if true, mass the sum of 
all experimental s must be one. Thus, the sum of calculated  s from the FIRMS model 
in Equation 4 must also be one. Consider three fragments 39, 41 and 61 m/z for tert-butyl 
chloride in Figure 3.1B as the only fragments used to calculate s and IRs. The paired 
data (i.e., the product ions m and m+1 m/z) for calculating s will be 39 and 40 m/z, 41 
and 42 m/z, and 61 and 62 m/z (Figure 3.1C). The logical proof is evaluated using 5 steps 










Table 3.1. Calculation of µ(s) using Equations 5 for tertbutyl chloride 
µ(s) Equation 
𝜇39,78 𝛼39,77 [3 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)]
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
𝜇40,78 𝛼39,77 [3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  3 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)]
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
𝜇41,78 𝛼41,77 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
𝜇42,78 𝛼41,77 [3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  5 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)]
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
𝜇61,78 𝛼61,77 [(𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  3 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)]
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
𝜇62,78 𝛼61,77 [2 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  3 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)]
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
Step 1: Calculate s. 
Step 2: Determine sum of s given by 𝜇39,78 + 𝜇40,78 + 𝜇41,78 + 𝜇42,78 + 𝜇61,78 + 𝜇62,78 
and also calculated as follows: 
 





3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙) {𝛼39,77 + 𝛼41,77 + 𝛼61,77} + 6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙) {𝛼39,77 + 𝛼41,77 + 𝛼61,77}
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
 
Step 4: Given that 𝛼39,77 + 𝛼41,77 + 𝛼61,77 = 1, simplify step 3 further to the following 
fractions. 
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙) ∗ 1 + 6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙) ∗ 1
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙) + 6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
3 (𝜎13𝐶12𝐶21𝐻635𝐶𝑙)  +  6 (𝜎12𝐶32𝐻1𝐻535𝐶𝑙)
 
 
Step 5: Simplify the numerator and denominator, which gives a solution of 1. 
  
The calculations in Table 3.1 show that the model predicted by FIRMS isotope 
ratios calculations is accurate for tert-butyl chloride. For all FIRMS molecules, the 
theorem stands to be true as the sum of µs are found to be one for the paired isotope data 
for precursor ion M+1 and precursor ions M+2. However, the M+2 µs must include all 
the three product ions m, m+1, and m+2 m/z.  
3.2.5 Analytical solvers 
As alluded to earlier, the calculation of IRs using FIRMS method relies on the 
ability of nonlinear solvers to optimize solutions from composite MOFs for isotope 
frequencies, a process known as a multi-objective optimization (MOO). The MOF, 
c(𝑥)⃑⃑⃑⃑ = |𝑓(𝑥 )𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑓(𝑥 )𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙| is the sum of single objective functions 





Equations 5 and 6 are nth order nonlinear polynomial functions that are also 
differentiable. The terms and variables of these equations depend on the number of atoms 
present in a fragment. The number of equations computed depends on the number of 
fragments considered for a particular FIRMS model. In all circumstances, the models 
created by FIRMS are complex because there are at least two atoms of the same 
elements, such as carbon and hydrogen that creates largely complex polynomials. Thus, 
solving for the isotope abundances of IRs of each atom location in molecules that have 
more than two atoms is analytically difficult, and can take an unpredictable amount of 
time without finding solutions.  
However, the numerical solving approach offers relief for the analysis of the 
complex FIRMS models. Because FIRMS models are described by a complex nth order 
polynomial and differential functions, numerical solvers offer an incredible advantage 
over analytical solving because they are fast, accurate, and may be the only available 
method to solve the complex nonlinear problem produced by FIRMS.  
In the numerical solver approach, the calculated and experimental 𝜇𝑖𝑠 (Equation 5 
and 6) are compared via a MOF, 𝑐 (𝑥)⃑⃑⃑⃑ . The numerical solver minimizes the objective 
function by evaluating the fractional abundances of all atoms in a molecule that gives 
satisfactory solutions. The solutions are comprised of fractional abundance values of the 
atoms present in the compound. 
3.2.6 Numerical Solvers 
 There are three categories of analytical solvers, namely simulation, optimization, 
and data mining that perform computations and numerical modeling. A computer model 





complex system that can be conceptualized. It is designed to show important features and 
characteristics of the complex system which is being studied and analyzed. It can provide 
meaningful understanding, predictions, and solutions to the problems investigated in the 
real system. A significant percentage of a model often represents the actual system.145 
Optimization involves finding the maxima or minima of mathematical functions 
sometimes subjected to constraints.146 Simulation optimization automatically finds the 
best solution of one or several variables that can be controlled. Optimization allows 
researchers to make better choices when all data are available. Simulation enables 
researchers to understand the possible results of decisions they do not have control over, 
considering a range of possible outcomes that are uncontrollable in any model.145-146 Data 
mining, on the other hand, is a process of obtaining implicit, formerly unknown and 
possibly important patterns and relationships from data.147  
3.2.7 Simulation optimization solvers 
For FIRMS analysis, coupling simulation and optimization solver is valuable 
because simulation replicates the structure of a molecule and the fragments that result 
from subjecting a compound through MS analysis, while optimization minimizes FIRMS 
MOF to determine the actual values of isotope frequencies subject to constraints. This 
process is known as the multi-objective optimization (MOO).  
3.2.7.1 Overview of the MOO formulation 
 Solving a MOO problem constitutes one major challenge i.e., finding a solution 
that is acceptable to all MOF. The MOF solution can be calculated through single 
objective optimization (SOO) (i.e., optimization of a composite objective function of all 





A general single-objective optimization problem is described as: 
minimizing (or maximizing) 𝒇(𝒙) subject to 𝒈𝒊(𝒙)  ≤ 𝟎, 𝒊 =  {𝟏, . . . ,𝒎} and 
𝒉𝒋(𝒙) = 𝟎, 𝒋 =  {𝟏,… , 𝒑} 𝒙 ∈  𝛀. A solution minimizes or maximizes the scalar 𝒇(𝒙) 
given 𝒙 is a n-dimensional decision variable vector 𝒙 =  (𝒙𝟏, … , 𝒙𝒏) in a space Ω. 
Notice that 𝑔𝑖(𝑥)  ≤ 0 and ℎ𝑗(𝑥) = 0 represents constraints that must be fulfilled while 
performing optimization. Ω  is a space that contains all possible x values that can satisfy 
the function 𝑓(𝑥) and constraints, where 𝑥 can also be a continuous or discrete vector and 
𝑓(𝑥) can as well be continuous or discrete.148 
The multiobjective optimization problem (MOO) is defined as: 
“a vector of decision variables which satisfies constraints and optimizes a vector function 
whose elements represents the objective functions. These functions form a mathematical 
description of performance criteria which are usually in conflict with each other. Hence, 
the term “optimize” means finding such a solution which would give the values of all the 
objective functions acceptable to the decision maker.”148 
The mathematical formulation of MOO is 
 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝒇𝒊(𝒙)
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 𝒙 ∈  𝛀 =  [𝒙 ∈  ℝ𝒏, 𝑔𝑗(𝒙) ≥ 0, 𝑗 = 1, 2, . . . , 𝑚]
}  (11) 
where  
𝒙 =  [𝒙𝟏, 𝒙𝟐 , . . . , 𝒙𝒏]
𝑻 
𝒇𝒊(𝒙) =  [𝒇𝟏(𝒙), 𝒇𝟐(𝒙), . . . , 𝒇𝒌(𝒙)], 
k is the number of objective functions, Ω is the decision space, 𝑥 ∈  Ω is the decision 





 In the SOO problem, the optimum solution minimizes the composite or SOF 𝑓𝑖(𝑥) 
subject to constraints. However, defining a minimum point for MOO at which all 
components of the objective function vector 𝒇𝒊(𝒙) are simultaneously minimized is 
practically implausible because a “utopia” point that can achieve that goal is rarely 
possible. Thus, a solution for Equation 11 is always unclear, because there is not a single 
unique point that can minimize all MOF simultaneously. This unique problem, therefore, 
gives rise to the search for optimality. It is different from solving a scalar optimization 
problem and requires finding optimum solutions to the vector MOO. In reality, there are 
infinitely many optimal solutions. An optimal solution exists where there are no other 
feasible solutions that can improve the value of a SOF without worsening the values of 
other objective functions. Therefore, there is not one unique solution; however, there are 
a set of pareto solutions found through the use of Pareto Optimality Theory.  The theory 
argues that 𝑥∗ is Pareto optimal if there exists no feasible vector 𝑥 which will reduce 
some criterion without increasing simultaneously at least another criterion for 
minimization process.148 Thus, Pareto optimal solutions have the characteristics that are 
required to find solutions for the vector MOO problem.149-152 
 Pareto optimality was first proposed by Edgeworth and Pareto and is defined as 
follows,153 
(1). A vector 𝒖 =  (𝒖𝟏, 𝒖𝟐 , . . . , 𝒖𝒎) is described as dominant over another vector 
𝒗 = (𝒗𝟏 , . . . , 𝒗𝒎), represented as 𝒖 < 𝒗, if 𝒇∀𝒊∈ {𝟏, . . . ,𝒎}, 𝒖𝒊  ≤  𝒗𝒊 and 𝒖 ≠ 𝒗. 
(2). Mathematically, a decision vector 𝒙∗  ∈  𝛀 is Pareto optimal if there is no 
another existing 𝒙 ∈  𝛀 such that 𝒇𝒊(𝒙) ≤  𝒇𝒊(𝒙
∗) ∀𝒊 = 𝟏, . . . , 𝒌 and 𝒇𝒋(𝒙) <  𝒇𝒋(𝒙
∗) for 





The definition can be interpreted to mean that Pareto solutions exist only if a 
solution point cannot be moved from one point to the other without negatively affecting 
other objective functions. A solution point is also a weak optimal point if it is impossible 
to move the point and improve all objective functions simultaneously.150 The vector of 
the objective function is only Pareto optimal if the corresponding decision vector x is 
Pareto optimal.149-150  
 A solution for a specific MOO formulation is sufficient for Pareto optimality, 
because it captures all SOF; thus, the method that establishes the solution is significant. 
But, it also undermines the objectivity of SOO because the formulation that provides the 
necessary conditions for a Pareto optimal point is a solution for that specific formulation 
and cannot be applied on a single SOO. In some cases, the solution for a specific 
formulation might not be  Pareto optimal, or with sufficient conditions, it will always be 
Pareto optimal that does not capture all of the Pareto optimal points.150 Therefore, 
decisions are often made to allow one of the problem solving processes, either MOO or 
SOO, depending on the objective of the decision maker. At no point can the two MOO or 
SOO be allowed to find a solution for the same problem. 
There are infinite Pareto optimal solutions for the MOO problem. Thus, user 
preference for specific or various objective functions is valuable in order to find a single 
solution. Given methods that include a priori articulation of preferences, users can 
specify preferences before running an optimization algorithm that determines a single 
solution suitable to the user preferences. There are other cases where users do not specify 
prior preferences but select a single solution from a representation of the Pareto optimal 





analysis, a weighted sum method for a priori articulation preference is used. Weighted 
sum method (WSM) allows the MOO problem to be cast as a single-objective 
mathematical optimization problem.149-150 
 Using the WSM to solve the problem represented by Equation 11 involves 
selecting scalar weights 𝑤𝑖 and minimizing the general composite reformulated Equation 
11 as the objective function represented as: 
   𝐦𝐢𝐧∑ 𝒘𝒊𝒇𝒊(𝒙)
𝒌
𝒊=𝟏        (12) 
   𝒔. 𝒕    𝒙 𝝐 𝛀, 
where 𝒘𝒊 ≥ 𝟎, ∀𝒊= 𝟏, . . . , 𝒌 and ∑ 𝒘𝒊 = 𝟏
𝒌
𝒊=𝟏  under convexity assumptions.
149 All the 
positive weights are assumed to minimize Equation 12 and provides the necessary 
conditions for Pareto optimality which means that the minimum of Equation 12 is always 
Pareto optimal.154-155 
3.2.7.2 Normalization in the WSM 
 Ideally, the scalar weights of each SOF are assigned by the decision maker (DM) 
or user based on the deep-rooted knowledge of the problem at hand. But because 
different SOF can have different magnitude, the normalization of the SOF is necessary to 
find a Pareto optimal solution consistent with the scalar weights assigned by the FIRMS 
user. Thus, the scalar weights are calculated as: 
    𝒘𝒊 = 𝒖𝒊𝜽𝒊,      (13) 
where 𝒖𝒊 are the weights assigned by the user and 𝜽𝒊are the normalization factors.
149 
 There are many ways of determining normalization factors, such as: 
















{𝒇𝒊(𝒙) 𝒙: 𝒙 ∈  𝛀 }; 
▪ normalization by the difference between optimal function values evaluated in the 
Nadir and Utopia points which gives the length of the intervals where the ideal 
objective function varies within the Pareto optimal set.149 
 
The first two normalization schemas are ineffective and impractical because the 
initial point,  𝑥0, does not provide accurate representation of the function behavior at 
optimality. 𝑓𝑖(𝑥0) equal to zero cannot be used, and using optimal solutions to individual 
objective functions can distort the scaling because optimal values are not associated with 
the geometry of the Pareto set.149 
In the third normalization scheme, it is easy to determine the ranges of the 
objective Pareto optimal set which provides incredible information for the solution 
process. The initial step is to determine 𝒛𝒊
∗ = 𝒇𝒊(𝒙
[𝒊]) ∈  𝓡 values of the ideal objective 
vector 𝒛∗  ∈  𝓡𝒌 by minimizing the individual objective function subject to user-defined 






{𝒇𝒊(𝒙)  ∶ 𝒙 ∈  𝛀}.        (14) 
Two ideal objective vectors 𝒛𝑼 = 𝒛∗ known as the Utopia point which provides the 
lower bounds, and Nadir point 𝒛𝑵 components that define the upper bounds can be 
defined for the Pareto optimal set using the ideal vector 𝒛∗  ∈  𝓡𝒌. The Nadir point can be 
formulated as: 




[𝒋])) , ∀𝒊= 𝟏, . . . , 𝒌.





Using the difference of optimal function for normalization the values for 𝜃𝑖 can be 
formulated as, 





149           (16) 
The normalization schema using Nadir and Utopia points provides the best normalization 
solution because the objective functions are normalized by the true intervals of their 
variations within the Pareto optimal set. Thus, all objective functions normalized are 
bounded by 





𝑼  ≤ 𝟏,       (17) 
which gives equal magnitude to each objective function.149 
In practice, Nadir and Utopia points can be estimated without finding solutions 
for any optimization problem, rather by evaluating random sampling points x subjected to 
user-defined constraints. For FIRMS, the points were calculated as maximum and 
minimum of each objective function evaluated at the upper and lower boundaries defined 
by the user.149 
 The sub weights, 𝑢𝑖, are assigned by the user; for example the Ranking Sum (RS) 
method. In this method, the sub weights are the individual ranks normalized by dividing 
the sum of the ranks. The RS function is formulated as follows:156  





     (18) 
where k is the total number of objective functions,  𝑟𝑖 is the rank of the i
th objective 
function and 𝑖𝑡ℎ = 1, 2, . . . , 𝑛.156 
Equation 18 can be further be written as: 
    𝜇𝑖 =
2(𝑘+1−𝑟𝑖)
𝑘(𝑘+1)





 The WSM has a major weakness for linear objective functions and linear 
problems that use simplex-type methods to find solutions for weighted sum functions. 
Because, for any linear function, the simplex method evaluates the vertex to find 
solutions and ignores the weights that can yield solutions in the interior of the linear face 
of Pareto optimal set. This problem is known to have optimality issues, and the vertex 
solutions on the Pareto optimal set are not practically valuable solutions. An optimal 
solution might also experience enormous jumps when there is a slight change in weights 
but will not experience the same jumps when there are broad changes in weights, a 
problem known as sensitivity issues. However, the probability of encountering the same 
problems with non-linear functions is very low. Because, for example, for polynomial 
objective functions, the efficient frontier of the Pareto optimal is non-linear. And one of 
the ways to overcome linearity of Pareto face is to convert the objective functions into 
polynomials; for example, converting them to quadratics by squaring the functions.149 
 Fortunately, FIRMS functions are not prone to WSM problems since they are all 
polynomials (nonlinear). Moreover, FIRMS functions are further classified as non-linear 
(nth order polynomials and multi-variable differential functions), non-convex and non-
smooth functions. This classification was very significant in selecting the simulation 
optimization algorithms for MOO problems. Thus, understanding nonlinear, nonconvex 









3.2.8 Nth order polynomial and multi-variable differential functions  
Polynomials include 𝑓(𝑥) functions, such as quadratic, cubic, quartic and 
functions with nonnegative integer powers of x. A polynomial of a degree n is a function 
of the general form157 
                        𝑓(𝑥) =  𝑎𝑛𝑥
𝑛 + 𝑎𝑛−1𝑥
𝑛−1+. . . +𝑎2𝑥
2 + 𝑎1𝑥 + 𝑎0    (20) 
where the a(s) are real numbers also known as coefficients of the polynomial.  
From the general formula, an example function of n = 4, such as modified Ferrari 
equation, can be formulated as, 158-159 
                                       𝑓(𝑥) = 𝑥4 + 𝑥3 − 6𝑥2 − 6𝑥 + 36     (21) 
The function in Equation 19 is also known as a quartic polynomial, 157 and has a graph 
shown below.  
 
Figure 3.2. 3D plot of a 4th degree polynomial function represented by Equation 21. 
 
A differential function contains term(s) involving derivatives of the dependent 





equations are functions. For example, Equation 22 shows a simple differential 
function.160-163 
    
𝑑𝑦
d𝑥
= 4𝑥3 + 3𝑥2 − 12𝑥 − 6    (22) 
The functions are characteristics of the relationship between a continuous variable and its 
rate of change. Differential equations are widely used in applications such as FIRMS for 
Chemistry, Physics, Biology, Economics, Engineering, and other areas of natural 
science160-163. The functions represented by the FIRMS model are both polynomials and 
differential because there is at least a 2nd degree term in all equations. 
3.2.9 Isotope combinations and data structure algorithms 
FIRMS Equations 5 and 6 are both nth degree polynomials and are differentiable. 
When expanded a specific example, such as tertbutyl chloride, the functions become 
Equations 7, 8 and 9. These equations represent complex polynomial functions with 
several independent variables. The degree of the polynomials depends on the number of 
atoms of individual elements (e.g., C, O, and H), n, where n = 1, 2, 3, 4, etc. Thus, unlike 
general polynomial function described in Equations 11 and 12 above, the terms and 
coefficients of FIRMS functions are independent of each other and only dependent on the 
atoms present in that term. The coefficients of each term also depend on the probability 
of occurrence of product ion in the molecular fragmentation pattern. For example, given 
Equation 8, the numerator has two terms, each of which have a coefficient of 3, meaning 
that the fragment obtained by changing an isotope of carbon or hydrogen for m/z 40 can 
only occur three times for both elements. Meanwhile, in the denominator, the coefficient 
of the first term is 3, while for the second term it is 6. For the precursor ion in question, 





carbon, while there are 6 possible molecule combinations that can be formed by replacing 
a hydrogen atom with a deuterium atom.  
Determining the possible combinations of atoms which make up a particular 
fragment leading to a polynomial function, can be complicated. Using the general laws of 
permutations, it can be shown that the number of possible combinations increases 
exponentially, depending on the number of atoms in a molecule. For example, potential 
combinations of tertbutyl chloride molecules with the chemical formula C4H9Cl that can 
occur by changing an isotope by mass of 1 is equivalent to 213 (i.e., the number of carbon 
and hydrogen atoms as the power) which gives 16384 possible combinations. However, 
the number of utilized combinations is 3 for carbon and 6 for hydrogen. Therefore, 
producing 213 combinations and filtering out unwanted combinations to form FIRMS 
polynomial equations is a complex task that requires specialized data structure 
algorithms.  
There are many different types of data structures, in which data are arranged 
sequentially. Data structures have logical starts, and logical ends, with elements 
embedded in them, and are used to store and organize data. The choice of data structure 
depends on several factors, such as what needs to be stored, the cost of frequently 
performed operations, computer memory usage, and the ease of implementation.164 
We developed two types of data structures algorithms for FIRMS, tree (for non-
linear functions) and stack (for linear functions), and their performance was tested with 
FIRMS models. Even though FIRMS functions are non-linear, the linear stack data 
structure easily produced the combinations of atoms for the molecular fragments of 





example, in a company, sits the chief executive officer (CEO) at the top, with two 
deputies (i.e., president and chief technology officer (CTO)) who also have deputies 
called managers. Below the managers are the supervisors who oversee workers. The 
company, therefore, can be described by a tree. A logical model of a tree can be 
represented such that the top hierarchy is the root, and from the root there are branches 
(inverted tree diagram). In computational modeling, the tree is a non-linear collection of 
entities called nodes linked together to simulate a hierarchy. In each node, beginning with 
the root, there can be different types of data (integer, character, or string) stored in the 
node and may contain some reference to some other nodes, also known as “children.” In 
the tree diagram, the only direction used is from the top (root) to the bottom, or from 
ancestors to descendants (grandchildren). A tree can be a recursive data structure if it 
contains a distinguished root and subtrees in which the arrangement is such that root of 
the tree contains links to root of the subtrees. A tree with N nodes can have only N-1 
links or edges represented by an arrow. The depth of x in a tree is defined as the length of 
the path from the root to node x, or the number of edges in the path from root to x. The 
height of a node entry is defined as the number of edges in the longest path from x to a 
leaf node or height of a root node. A leaf node is a node without linked nodes compared 
to other nodes. The height and depth of a tree are two different properties and may or 
may not be the same. A tree data structure may be binary, with nodes that have a 
maximum of two edges.165-166 Figure 3.3 shows an example of tree (binary) data structure 
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Figure 3.3. A tree diagram of BrO3 with tree depth four. 
 
 The root of the tree (BrO3 with a molecular mass (M) of 129 m/z) represents a 
molecular ion mass of M+2. From the root, each node is occupied by atoms in the 
molecule. The first level (parents) shows 81Br picking up 18O (left child) and 16O (right 
child), or 79Br (right branch doing the same. The second level in the tree shows the 
molecule picking up 18O and 16O for each of the first offspring (first children). The 
integers over the nodes represent the remaining mass after picking an atom, or a “child.” 
For example, starting with 129 m/z at the root and following the left branch with 81Br, the  
mass remaining is 48 (i.e., 129-81). While on the other side, the right path gives a 
remainder of 50 (i.e., 129-79). These processes continue from the first to the third 
oxygen. Notably, in the tree diagram, some paths discontinue before making the target 
molecule BrO3. Also, some paths in the diagram have all four atoms; however, there is 
still mass remaining.  Therefore, the combination is also not valid. For the two scenarios, 
the combinations are pruned. This tree diagram has a tree depth of 4. The pruning can be 






Figure 3.4. Represents a pruning process of a tree diagram of BrO3 with tree depth four 
 
  Other examples of tree diagrams for FIRMS include dichloromethane (DCM) 
(Figure 3.5), and folic acid (Figure 3.6). For DCM, shown in Figure 3.5, with CH2Cl2, 
there are 3 elements, each with 2 isotopes giving a total of 6 atoms. This is tree depth of 6 
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Figure 3.5. Represents a tree diagram of dichloromethane (DCM) with a tree depth 6. 
 
The tree data structure for folic acid (C19H19N7O6) is shown in Figure 3.6. In folic 
acid molecule, there are 4 elements. Thus, this is a tree depth of 51 which gives 






Figure 3.6. Represents a tree diagram of folic acid with a tree depth 51. 
 
 In the last tree diagram example, sorting the relevant molecule combinations is a 
tedious process, and can lead to a high cost in computation time, memory use and the 
difficulty of implementation. Thus, another data structure type is desired which does not 
have limitations of the tree-type data structure. In this case, a linear data structure, known 
as stack, was implemented for FIRMS models.  
 Stacks are an Abstract Data Type (ADT) that can be logically constructed as a 
linear structure that represents a real physical structure, in which insertion and deletion 
can be implemented, such as with a deck of cards or a pile of plates. In real applications, 
the stack structure allows operations to take place at one end only. For example, plates or 
cards can only be removed or added at the top of the pile. This idea is also known as 
Last-In-First-Out (LIFO). The argument is that the element added/inserted last, is 
C19H19N7O6
C13 C13










accessed first. Any process that would allow operations from the bottom is eliminated. 
The syntax for insertion is known as a push operation, and removing elements is known 
as a pop operation. Stack can be implemented using Array, Structure, Pointer, and Linked 
List. A stack can be a fixed size or can have the ability to resize which is an important 
feature for FIRMS models. 
 The stack data structure was more advantageous for FIRMS applications, and 
thus, replaced the tree data structure for determining isotope combinations that could 
produce a particular fragment mass. It gives FIRMS the ability to create a combination of 
atoms to produce a molecule and add it into a stack, test if it meets the requirements and 
pop out unwanted combinations. Compared to the tree method, this method consumed 
less time, required a relatively small amount of memory, and was easy to implement. 
 Within the FIRMS software, a computer algorithm was built with a function that 
was comprised of a string (p) variable list and integers (massDiff) to represent the atomic 
mass difference between the base mass M and precursor ion M+1. For example, if p = C3 
and massDiff = 1 the two strings of carbon atoms produced by the functions are 
12C12C12C and 13C12C12C as shown in Figure 3.7. This idea can be expanded to a 
molecule like DCM (CH3Cl2) where the function is called for each element C, H, and Cl 
to produce a string of isotopes and the mass difference of interest. 
 When the individual element lists are created (i.e., C, H, H, H, Cl, Cl) by the 
isotope combination algorithm they are pushed on the stack creating the initial state of the 
first element in the list as shown in Figure 3.7. Each element list produced in the stack 
also has a multiplier embedded in them. The product of the multiplier for the elements in 





of the first elements have been added to the second element in the list the last one is 
added and inserted into the second stack as shown in Figure 3.8 by the arrows. The 
process continues until all elements have been combined and added to the stack as shown 
in Figure 3.9. The stack size depends on the number of molecule combinations and can 
be N = 1, 2, 3, … k where k is an integer. In the final step, the completed molecular 
formula is double checked to make sure it is accurately equal to the required mass 
difference, as shown in Figure 3.10. Any undesired molecular formula is eliminated from 
the corrected list. At this point the algorithm has enough molecular combinations with 
accurate isotopes. These combinations are then passed to Equations 5 and 6 which further 































Figure 3.8.  A string of carbon atoms combining with hydrogen atoms in stack data 














Figure 3.9. A string of combined carbon, hydrogen and chlorine atoms in a stack data 




































Figure 3.10.  A stack of combined atoms in arranged on top of each other like plates 
stack together. The right side are the molecular formulas that have been crossed checked 
for accuracy 
 
 Another example of the implementation of stack data structure is shown using a 
BrO3 molecule. A list is created {Br, O, O, O} for all the atoms in the molecule. Then an 
atom string is built up which comprises stable isotopes of each atom. For this example, 
79Br and 81Br are put together on the stack as the first atoms of two possible molecules as 
shown in Figure 3.11. The two stable isotopes are popped off the stack and then added to 
the stable isotopes of (16O, 17O, 18O), as shown in Figure 3.12. The process (i.e., brute 
force) continues until all the stable isotopes of oxygen are added as shown in Figure 3.13. 
The brute force method proceeds and eventually produces molecular formulas for all 
possible atom combinations. The molecular formulas are cross checked again to eliminate 
the unwanted combinations. For a mass difference of 2 (e.g., base mass M+2), the 
process can be optimized by keeping a running count of the additional mass as shown in 
Figure 3.14. The process continues until the full molecular formula is reached, and all 
unwanted combinations that exceed the mass difference are eliminated, as shown in 
Figure 3.15. Then the accepted isotope combinations are used to calculate fractions based 
on isotope frequency (probability).  
 

































Figure 3.14. A stack structure of BrO3 molecules describing stack diagram with three 






















































Figure 3.15. A stack structure of BrO3 molecules describing stack diagram with four 
atoms and showing the elimination of unwanted structures. 
 
Calculating fractions for isotope combinations produced by stack data structures 
can be described as events and involves two methods of addition and multiplication. For 
single events, the simple mathematical rule of multiplication is employed. However, if 
two events occur randomly with the same outcome but following two different paths, the 
probability calculations become complicated. For example, in isotope combinations, two 
different fragments might have the same mass, but different molecular ion formulas. The 
same outcome, which is the calculated mass, must be determined in two different ways to 
represent different paths, e.g., 13C or 2H isotopes that contributes the same change in mass 
by one unit. Both isotopes give a change of molecular mass by 1, but the two paths 
leading to the mass difference of 1 must be determined independently. In such 
circumstance, the probability tree diagram can be invoked which follows the rules of 



















determine the probabilities of independent events following a different path but with the 
same outcome. For example, the tree diagram in Figure 3.15, shows two independent 
events that would likely lead to the same outcome using independent paths. The 
likelihood that Hawi (H) will watch news (NW) when she wakes up can follow two 
paths, i.e., Hawi (H) wakes up, drinks coffee (C) and watches news (NW) or Hawi wakes 
up, does not drinks coffee (NC) and watches news (NW). The probability that Hawi will 
watch news can be then calculated as the sum of P (C n NW) and P (NC n NW) which 
results in a value of 0.5 given that there are equal chances of the first two events 
occurring, and where P is the probability/likelihood of the event happening. In Figure 
3.16, the same probability result of 0.5 can be arrived at using the sum of probabilities P 
(C n NNW) and P (NC n NNW). But that cannot be allowed as a solution, since none will 
result in Hawi watching the news. And such solutions are thus eliminated from the 
overall results using computer algorithms in applications that involve complex analysis 
such as FIRMS analysis. 
The same knowledge of probability tree diagram is applied in FIRMS to 
determine the probability that a particular fragment of M+1 will have a specific 
combination of atoms that will produce acceptable results and filter out unwanted 
combinations with similar solutions. After adverse combinations are eliminated, the 
multiplication and addition rules are applied. Since the frequency (isotope abundance) of 
occurrence is known, the probability of atom combinations that produces the mass M+1 
can be calculated as multiples of the frequencies raised to the power of the number of 
atoms as shown in Equations 5-9. The probabilities of possible combinations that produce 






Figure 3.16. A flow chart of a probability tree diagram showing the path of events. 
 
The isotope combinations produced by the computer algorithm are used to 
generate Equations 5-9, which make up the MOF. As described earlier, these functions 
have the characteristics of nonlinear functions. Finding a solution for MOF described as 
MOO problems requires unique algorithms. Existing computer algorithms for finding 
solutions to MOO problems are built for specific types of functions, such as nonlinear, 
nonconvex, and nonsmooth functions (NSF), linear, convex and smooth functions, and 
nonlinear, convex and smooth functions. Thus, knowledge about the convexity and 
smoothness of FIRMS functions is significantly important to select the best solution 
algorithm.  
3.2.10 Nonconvex, constrained and non-smooth functions (NSF) 
 A function is defined as nonconvex if it has multiple minima.167 Often, 
optimization problems become numerically complex to solve when neither the objective 
functions nor constraints have a convexity structure. Constraints are conditions of an 





geometrically described as f: Rn R is convex if dom f  is a convex set and f (x + (1-) 
y)    f(x) + (1-) f(y) for all x, y  dom f, 0    1, as shown in Figure 3.17.169 
 
Figure 3.17. A graph describing a geometrical convex function f. 
 
f is concave if –f is convex.  f is strictly convex if dom f is convex and f (x + (1 - 
) y) <  f(x) + (1-) f(y) for x, y  dom f, x  y, 0 <  < 1.169 
 A function is described as non-convex if it is neither convex nor concave, and has 
wave-like shapes, i.e., troughs and crests. Non-convex functions are often assumed to be 
nonsmooth (a function without continuous derivatives within a certain domain) with 
several feasible regions, and many locally optimal points within each region described by 
a set of boundaries. Since non-convex functions are nonsmooth and discontinuous, the 
derivatives are impossible to compute. Hence, the function cannot be described as 
increasing or decreasing (i.e., a possible solution does not provide enough information 
about a given point that can give enough information). 
 Of course, the general explanation of a nonconvex and nonsmooth function 
cannot explicitly explain the convex properties of FIRMS models. FIRMS functions are 





nonsmooth. The procedure involves using vector and matrices in a given search space 
subject to constraints to explain the nonconvex properties of FIRMS functions. 
 Consider the objective function 𝑐(𝑥): ℝ𝑛 →  ℝ subject to constraints described by 
vector 𝑔𝑗: ℝ
𝑛 → ℝ for some integer (n) and isotope frequency (i). The function c(x) is 
also of the form   
 𝑐(𝑥 ) = |𝑓(𝑥 )𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙|                  (23) 
for the vector 𝑥  with isotope abundance frequencies as the variables, 𝑓 is a polynomial 
mapping from Rn  R, and 𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 is a constant calculated from the 
experimental data. Both the objective functions and polynomial functions are continuous 
with infinite derivatives, with the exception where 𝑓(𝑥 )𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 = 𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙.  
 The objective function mapping from ℝ𝑛  →  ℝ, which is continuous with 1st and 
2nd derivatives can only be convex if it has a positive definite Hessian matrix.170 The 
polynomial function 𝑓(𝑥 ) in Equation 15 is either smooth or nonsmooth and constrained 
to the convex n-cell defined by the isotope abundance frequency in 𝑔𝑗: ℝ
𝑛 → ℝ.171-172 
Using tert-butyl chloride and the polynomial 𝑓(𝑥 ), Equation 7 can be formulated as 
Equation 24. 
 
𝑓(𝑥, 𝑦, 𝑧) = 6𝜇𝑥3𝑦5𝑧 − 9𝜇𝑥3𝑦6𝑧 + 3𝜇𝑥2𝑦6𝑧 − 3𝛼𝑥3𝑦6𝑧 − 3𝛼𝑥3𝑦5𝑧   (24) 
where vector 𝑥  = (x, y, z). x, y, and z represent the isotope frequencies for carbon, 
hydrogen, and chlorine respectively, and  and  are empirical constants. The Hessian 







































= 36𝜇𝑥𝑦5𝑧 − 54𝜇𝑥𝑦6𝑧 + 6𝜇𝑦6𝑧 − 18𝛼𝑥𝑦6𝑧 − 18𝛼𝑥𝑦5𝑧    (26) 
𝜕2𝑓
𝜕𝑦∂𝑥
= 90𝜇𝑥2𝑦4𝑧 − 162𝜇𝑥2𝑦5𝑧 + 36𝜇𝑥𝑦5𝑧 − 54𝛼𝑥2𝑦5𝑧 − 45𝛼𝑥2𝑦4𝑧   (27) 
𝜕2𝑓
𝜕𝑧 ∂x
= 18𝜇𝑥2𝑦5 − 27𝜇𝑥2𝑦6 + 6𝜇𝑥𝑦6 − 9𝛼𝑥2𝑦6 − 9𝛼𝑥2𝑦5    (28) 
𝜕2𝑓
𝜕𝑦2
= 120𝜇𝑥3𝑦3𝑧 − 270𝜇𝑥3𝑦4𝑧 + 90𝜇𝑥2𝑦4𝑧 − 90𝛼𝑥3𝑦4𝑧 − 60𝛼𝑥3𝑦3𝑧  (29) 
𝜕2𝑓
𝜕𝑥 ∂𝑦
= 90𝜇𝑥2𝑦4𝑧 − 162𝜇𝑥2𝑦5𝑧 + 36𝜇𝑥𝑦5𝑧 − 54𝛼𝑥2𝑦5𝑧 − 45𝛼𝑥2𝑦4𝑧   (30) 
𝜕2𝑓
𝜕𝑧𝜕𝑦
= 30𝜇𝑥3𝑦4 − 54𝜇𝑥3𝑦5 + 18𝜇𝑥2𝑦5 − 18𝛼𝑥3𝑦5 − 15𝛼𝑥3𝑦4   (31) 
𝜕2𝑓
𝜕𝑧2
= 0           (32) 
𝜕2𝑓
𝜕𝑥𝜕𝑧
= 18𝜇𝑥2𝑦5 − 27𝜇𝑥2𝑦6 + 6𝜇𝑥𝑦6 − 9𝛼𝑥2𝑦6 − 9𝛼𝑥2𝑦5    (33) 
𝜕2𝑓
𝜕𝑦𝜕𝑧
= 30𝜇𝑥3𝑦4 − 54𝜇𝑥3𝑦5 + 18𝜇𝑥2𝑦5 − 18𝛼𝑥3𝑦5 − 15𝛼𝑥3𝑦4   (34) 
 
But 𝑓(𝑥 ) is not Hermitian since it is not equal to its conjugate transpose, i.e.,  
    𝐴𝐻 ≠ ?̅?𝑇       (35) 
where A is an n x n matrix, AT denotes the transpose of the matrix A, ?̅? denotes the 
conjugate matrix, and AH symbolizes the Hermitian which arises from the combined 
operation of taking the transpose and complex conjugate of complex matrices.173-174 





means the matrix is not positive definite. The additive inverse of the matrix also shows 
leading minor and second-leading minor which results to nonnegative semidefinite. 
These descriptions do not meet the criteria described below: 
let A = (𝑎𝑖𝑗)  be an n x n symmetric matrix and 𝐷𝑘 the determinant for k = 1…, n be the 
leading principal minors:  
     𝐷𝑘 = [
𝑎11 𝑎12 … 𝑎1𝑘
𝑎21 𝑎22 … 𝑎2𝑘… … …
𝑎𝑘1 𝑎𝑘2 … 𝑎𝑘𝑘
]     (36) 
Then, A is positive definite if and only if 𝐷𝑘 > 0 for k 1…, n. A is negative definite if 
and only if (−1)𝑘𝐷𝑘 > 0 for k = 1…, n (i.e., if and only if the leading principal minors 
alternate in sign beginning with 𝐷1). A is positive semidefinite only if all its principal 
minors are nonnegative and, A is negative semidefinite only if its kth order principal 
minors are nonpositive for k odd and nonnegative for k even.175-176 
FIRMS equations were tested against the principles described above to 
demonstrate that the matrix in Equation 25 cannot be convex or concave on the nth cell it 
is constrained. Thus, the FIRMS polynomial function f(x) in Equations 6 and 7 are 
nonconvex, hence, all FIRMS functions are nonconvex. 
 Additionally, the nonconvex and nonsmooth property of FIRMS functions were 
tested using computer algorithms in Analytical Solver SDK Platform acquired from 
Frontline Solvers. FIRMS functions showed the presence of many local extrema within 
the constrained boundaries, further evidence of nonconvex and nonsmooth functions that 
require nonlinear and nonconvex optimization algorithms. Such algorithms perform a 
random sampling of all possible solutions to determine the best solutions. These methods 





with the negligible difference in every analysis. They are entirely dependent on the points 
sampled.148 
3.2.11 Solver algorithms 
 There are few known solvers for analyzing nonconvex and nonsmooth nonlinear 
models which have the characteristics of multiple feasible regions, multiple local optima 
within given regions, discontinuity, nonsmooth behavior, and lack of general information 
about the slope or derivatives in the direction of increasing or decreasing function. There 
are currently three algorithms for solving nonconvex and non-smooth complex problems 
such as FIRMS functions. They are Evolutionary/Genetic Algorithm, Tabu Search and 
Scatter Search Algorithms.  
3.2.11.1 Evolutionary/Genetic Algorithms (EA/GA) 
 Mathematical problems have three types of solutions: exact answers or roots, 
optimal, or extrema. In the case of optimal and extrema, the best solution is often 
determined relative to the problem being analyzed, the solution method, and the accepted 
tolerance values. Optimization is the process of altering the input of mathematical 
methods to find the minimum or maximum output. The input is comprised of variables, 
the mathematical method referred to as an objective function, and the output is the 
solution of an optimized objective function.177  
 In a real physical system where complex nonlinear problems exist and entropy 
plays a significant role, it is quite difficult to determine the best solution. Quantum theory 
implies that there are infinite dimensions that are different and correspond to decisions 
made. A small change in quantum systems can result in complex and random results. 





complex. Thus, the high number of complex systems has demanded the development of 
sophisticated solvers. Optimization algorithms were designed as primary tools required to 
solve highly complex problems encountered when analyzing nature, and designing or 
predicting results.177 As shown in Figure 3.18, there are six categories of optimization 
algorithms.  
 






Finding a solution to a problem can be seen as searching through a defined or 
non-defined space for possible solutions. Since the main objective is finding “the best” 
solution, the task thus bears the characteristics of optimization. For relatively small 
search spaces, there are classical methods that are suited for such problems, whereas for 
larger spaces, distinctive artificial techniques are used, such as EAs/GAs 177-178 
Evolutionary/Genetic algorithms (EA/GA) represent a popular meta-heuristic 
optimization and search technique guided by the principles of genetic evolution and 
natural selection.159-160 This method was invented by John Holland over a decade 
between the 1960s and 1970s. It was later advanced and introduced to research by 
Holland’s student, David Goldberg, when he solved a complex problem involving the 
control of gas-pipeline transmission for his dissertation research.177 
The multi-objective EA has appealed to many researchers because it possesses 
many readily apparent advantages. EA can optimize with continuous, or discrete 
variables and functions without derivative information. The algorithm performs a 
simultaneous search from a broad sampling of the objective function while handling a 
large number of variables. EA can couple with parallel computers and optimize variables 
with extremely complex objective functions. It  provides a list of optimum variables, 
performs optimization with encoded variables, addresses discontinuity, can solve 
nondifferential and nonconvex problems with multiple peaks, and can acquire the Pareto 
front in analysis.151, 177 
There are two approaches to solving MOO problems. One involves the use of a 
single composite function or optimizing one objective function while the rest are 





complete Pareto optimal solution set or a representative subset. As discussed previously, 
Pareto optimal solutions are nondominated with respect to each other. The single 
composite function with weighted sum method was applied in the optimization of FIRMS 
models.179-180 
In EA optimization, a solution vector 𝑥 ∈  Ω is known as an individual or a 
chromosome. They are of discrete units called genes. Genes control single or multiple 
features of the chromosome. In the original implementation of EA, Holland assumed that 
genes were represented by binary digits. However, modern EAs have varied gene types. 
Usually, a chromosome relates to a specific solution x in the feasible space. As a result, it 
requires mapping mechanisms between the feasible solution space and the chromosomes 
which is a process known as encoding.178-179 
A collection of chromosomes is known as the population which is initiated 
through a random process. During optimization, the search evolves, as does the 
population including the fitness functions. The two operators used to generate new 
solutions in the EA are the crossover (the most important operator) and mutation. During 
crossover two chromosomes known as parents combine to form new chromosomes or 
offspring. These parents are selected among the existing chromosome population with 
good fitness in order for the offspring to inherit good genes that make them fitted parents. 
Through iterative application of the crossover operator, the chromosomes with good 
genes survive in the population, which eventually leads to convergence of the optimum 
solution.178-179  
The function of the mutation operator is to introduce random changes into the 





the size of the chromosomes. Mutation is fundamentally significant in GA because it 
reintroduces genetic diversity back into the population which helps the algorithm 
overcome local optima.178-179 
Similar to biological processes, the reproduction comprises a selection of 
chromosomes for the following generation. The fitness of individuals in a population 
determines their probability of surviving through generations. The selection process 
depends on how fitness functions are applied. Popular selection procedures include 
proportional selection, and ranking.179  
The GA algorithm used for the FIRMS model optimization was built by Frontline 
Solvers utilizing Evolution Programs (EP) referenced in Michalewicz.178 It uses a 
floating-point representation. The mutation methods are implemented as uniform, non-
uniform (time-dependent), and bounds. The crossover methods include quadratic 
interpolation following controlled random search algorithm (CRS6)181-182  and total and 
partial arithmetic crossover (convex combination). However, in general, all GAs/EAs  
methods follow the process described by:179 
Step 1 
Set t = 1, Produce N solutions randomly to form the first population, P1 and 
evaluate the fitness of solutions in P1. 
Step 2  
Crossover: Produce an offspring population S1 through the following process: 
2.1. Select two solutions x and y from population P1 based on fitness values. 






 Mutation: Mutate individual solution 𝒙 ∈  𝑺𝟏 using a predefined mutation  
rate. 
Step 4 
Fitness assignment: Assess and assign a fitness value to individual  
solutions of 𝒙 ∈  𝑺𝟏based on its objective function value and infeasibility. 
Step 5 
 Selection: Choose N solutions from S1 based on their fitness and  
replicated them to 𝑷𝒕+𝟏. 
Step 6 
If the termination criteria is met, the process is stopped and the search  
returns to the existing population otherwise 𝒕 = 𝒕 + 𝟏 and Step 2 is repeated. 
3.2.11.2 Tabu search and Scatter search algorithms 
There are other meta-heuristic optimization methods other than GAs/EAs that 
have been shown as very effective in finding solutions for complex physical problems. 
For example, they are effective for systems with nonlinear objective functions or 
constraints with the possibility of a large number of discrete variables or nonsmooth, 
discontinuity and presence of uncertainty in important data. Thus, to solve such complex 
systems, researchers have trusted other metaheuristic methods, such as Tabu Search (TS) 
and Scatters Search algorithms (SS).180, 183-184 
3.2.11.2.1 Tabu search algorithms 
Tabu search was developed as a computational algorithm for solving 
combinatorial optimization problems with a wide range of applications, such as graph 





adapt and apply other existing methods (e.g., linear programming algorithms and 
specialized heuristics) which allows it to overcome the limitations of local optimality.185 
It was originally developed for combinatorial procedures applied in nonlinear problems186 
and also different groups of problems that include scheduling and computer channel 
balancing, cluster analysis, and space planning.187-190  
Caballero et al.191 developed a novel TS for combinatorial optimization problems 
with two approaches: 1) a local Tabu Search Algorithm that generated a list of locally 
Pareto-equivalent solutions (non-dominant solutions with respect to the neighboring 
solutions); 2) a procedure that strengthened solutions with a path-relinking strategy.191 
Path relinking strategies were developed for use in TS and SS algorithms, Greedy 
Randomized Adaptive procedures and discrete optimization field.180, 192-194 The strategy 
follows the underlying principle that the direction of the path in a design space can be 
better used to guide the search in that direction than a random one, with the hope of 
finding good points. The direction (or path) can be determined by use of initial point and 
a reference point. The reference is the best-known solution in the search space. For 
example, given two points x and y (reference point) of a vector, the search space between 
the two points is a linear combination of the vector variables in the space, and as such the 
retained information about the reference point can lead to good solutions points.180, 192 
Jaeggi et al.180, 195 developed the first multi-objective TS variant that is widely used today 
for unconstrained functions and constrained optimization problem.  
3.2.11.2.2 Algorithm  
 The TS is sequential and iterative, in which the search starts at a chosen point and 





The recently selected points are stored in the short-term memory (STM) and the search is 
not allowed to return to the values. Optimal points are stored in medium term memory 
(MTM) and are used for strengthening and directing the search on areas of the search 
space with known good objective function values. The long-term memory (LTM) keeps 
the record of regions of the search space explored and is used to strengthen and focus the 
search in regions less explored. This is done by dividing each design variable into n 
regions and keeping the count of evaluated solutions in that region. After a successful 
addition to MTM, the process is reset using a counter until the counter reaches the user-
specified value, and then the solution to the problem is produced.180 
 Mathematically, TS optimization can be applied in minimization via the 
following steps. 
Using Equation 10, one trial solution is selected in the space 𝒙 ∈  𝛀. A subset 𝛀(𝐬) of 𝛀 
is also created in the form: 𝛀(𝒔) →  𝛀. The space associated with 𝒙 ∈  𝛀 is then defined 
in the subset 𝑺(𝒙) that consists of the moves 𝒔  𝑺 that are applied for the x values. 
Those elements in s are obtained by a non-Markovian function that uses information 
stored from search process extended to t iterations in the past, where t can be a constant 
or variable depending on the optimization problem. The values in s are well guided by a 
set of tabu conditions, such as linear inequalities or logical relationships which are 
expressed indirectly in the form of a trial solution x; for example, 𝒔(𝒙)  =  {𝒔  𝑺: 𝒔(𝒙)} 
that may or may not defy the set tabu conditions. A simple tabu search process is 








Select an initial 𝒙  𝛀 and let 𝒙∗ : =  𝒙. Set the iteration counter 𝒕 =  𝟎 and begin 
with S empty. 
Step 2 
 If S(x) – s is empty, go to Step 4. 
Otherwise, set 𝒌: =  𝒌 + 𝟏 and select 𝒔𝒌  ∈ 𝑺(𝒙) −  𝒔 such that 𝒔𝒌(𝒙) =  
OPTIMUM(s(x)):  
𝒔  𝑺(𝒙) –  𝒔. 
Step 3 
Let 𝒙: =   𝒔𝒌(𝒙). If 𝒇(𝒙)  <  𝒇(𝒙 ∗), where x* denotes the best solution currently 
found, let x*: = x. 
Step 4 
If a selected number of iterations has elapsed either in total or since x* was last 
upgraded, or if 𝑺(𝒙) –  𝒔 =    (where  is an arbitrary value) upon reaching this 
step directly from Step 2, stop. 
Otherwise, update s (as subsequently identified) and return to step 2.185 
 
In the above Tabu optimization: 1) s provides the constraints values, therefore the 
solution found depends on values of s and the update process in Step 4; 2) there is no 
reference to the condition of local optimum with the exception of areas where the local 
optimum implicitly provides a better solution from previous values, and 3) the best move 





 Tabu search demonstrates its superiority over other classical optimization 
methods through solving a problem by use of best available values that do not lead to 
inferior solutions. Also, local optimum values do not provide an obstacle, therefore 
enhancing the speed at which the local minimum might be considered and abandoned if 
necessary. 185 The tabu search algorithm is recommended in many circumstances where 
other traditional solvers cannot optimize complex nonlinear functions and find the best 
global minimum solution. 
3.2.11.2.3 Scatter Search Algorithms 
 Glover194 developed the scatter search method for finding starting solutions and 
trial solutions of a function. It uses initialized values that are purposely generated to 
account for the behavior of the function in numerous parts of the solution search space. It 
works by orienting its explored values relative to a set of reference points. The reference 
points might consist of good solutions found by prior problem-solving or evaluation of 
functions.186 The scatter search performs the evaluation of a function through the 
following procedure:  
1. A starting set of solution vectors are generated by heuristic processes intended for 
the evaluation of the problem under analysis. Some best vectors of the selected 
subset are established as reference solutions. 
2.  New points are created consisting of linear combinations of subset of the existing 
reference solutions. These linear combinations are chosen to produce points both 
in and outside the convex regions covered by the reference solutions. They are 
also modified by a general rounding method to produce integer values for integer 





3. The best solutions generated in Step 2 are extracted as a group and then used as 
initial points for a new application of the heuristic processes in Step 1. The 
process is repeated until the required iteration limit is reached. An example of the 
method is shown in the Figure 3.19 below.186 
 
In Figure 15, the points labeled 1 through 16 are the designated central points for 
a given subregion of the simplex A, B and C. Point B is the main central point of A, B, 
and C. The points A, B C are not always used as the original points of reference. Any 
coordinate point such as 16, 11 and 13 could be established as reference points. For 
scatter search the choice relies on the distribution of the original points that are relative to 
each other and also their feasibility. In order to ensure the desirable limits for larger 
dimensions, the points produced as shown in the diagram are examined in a sequence 
ascending order, or an alternative sequence that depends on the gradient of the objective 
function contour. The generation of points continue until a desired point is reached as 






Figure 3.19. Generated vectors of scatter search process. 
 SS has three important features namely: 1) the linear combinations are built with 
the objective of producing weighted centers of selected subregions, hence allowing for 
nonconvex combinations that focus the centers into regions outside the original reference 
solutions. The dispersion pattern produced by such centers and their external focus are 
applicable for mixed integer optimization; 2) the process for selecting specific subsets of 
a solution are built to make use of clustering, hence allowing different types of important 
variation by producing new solutions within and across the clusters; 3) they support 
heuristics that are able to begin from infeasible solutions, therefore removing any 
restriction that selected solutions for re-applying the heuristic method must be possible.186  
 The SS and TA algorithm provided by the Frontline Solvers were built as solver 
engines using the work of Ugray et al.196  GAs/ EAs, TA and SS algorithms obtained 
from the Frontline Solvers were found suitable for analysis of IRs using FIRMS methods. 
They were integrated into the FIRMS graphical user interface (GUI) software.  
3.3 FIRMS Software 
3.3.1 Introduction 
 The software is a major component of the FIRMS method and the main 
computational tool used in the analysis of tandem MS data for FIRMS compounds. The 
models created by FIRMS using the information from molecular fragmentation data of 
compounds obtained via tandem mass spectrometry were impossible to solve analytically 
and too complex to solve numerically without the help of advanced computation. The 
complexity of the models and functions increased from simple molecules to complex 





rearrangement, bond formation and occurrence of protonation, deprotonation . Moreover, 
determining the combination of atoms that produce a particular fragment of molecular ion 
was extremely difficult for molecules with more than two atoms and elements. The 
complexity of FIRMS models and functions were further amplified by the molecules that 
fragment from a molecular ion mass M+2. Finding solutions for the FIRMS models and 
functions were therefore impossible by hand and necessitated the use of FIRMS software 
that is integrated with simulation optimization solver.  
3.3.2 C# programming language  
 There are dozens of computer programming languages in existence. For example, 
Alice, APL, COBOL, Pascal, Eiffel, FORTRAN, Haskell, Mercury, ML, Mondrain, 
Oberon, Perl, Python, RPG, Scheme, Smalltalk, C, C++, Visual F# and C# among many. 
We chose to build the FIRMS software in C#197-198 language for the reasons discussed 
below. 
 C# was originally created from scratch for .NET, which is a platform in which 
computer programs run and was designed as a new programming paradigm. It is not an 
operating system, like Windows platforms, but it is a layer between the operating system 
and other applications. Thus, it offers a platform for developing and running computer 
code that is easy and efficient to use with a set of development tools. Some of the 
standard features of .NET are:197 
• Multilanguage independence: It supports the development of computer 
applications using a number of programming languages i.e., Visual Basic, C# and 
C++ and also third-party languages that compile to the established Microsoft 





developed in different languages like Visual Basic and C# then translated to a 
common IL. 
• New Framework base classes: It has a class library, which provides an expansive 
collection of more than 2500 reusable classes available to the .NET languages. 
• Dynamic Web pages and Web services: .NET can deploy applications over 
intranets or internet using ASP.NET, ADO.NET and XML which allow access to 
relational databases, and import and export data through internet web. 
• Scalable component development: .NET supports object-oriented programming 
and development that is faster and easier in terms of performance. It allows the 
creation of components of codes as individual entities, and can be kept 
independently, reused or combined with other applications. These components 
can be created in different languages. 
 
For these reasons, the .NET platform was used for FIRMS. Thus, it was very 
convenient to use C# programming language since it was created and designed for the 
.NET platform. The large number of classes included as part of .NET could, therefore, be 
used and new classes easily designed in C# language. As a result, it would reduce the 
algorithms and programming codes needed for FIRMS software. Moreover, C# coupled 
together with .NET Framework classes, offered an opportunity to incorporate and use 
emerging Web standards, for example, Hypertext Markup Language (HTML), Extensible 
Markup Language (XML), and Simple Object Access Protocol (SOAP) which makes it 
easy to download updates for FIRMS software via internet. Additionally, the Visual 





interfaces (GUI) which is an essential component of FIRMS software. C# also offers 
excellent data handling speed to which C and C++ programmers are used to. C# also 
enables programmers to build packages available over the internet using many standard 
features available only in Java, Common Gate-way Interface (CGI), or PERL.197 Thus, 
users who would like to couple their applications with FIRMS would find it easy to do so 
without having to convert their apps algorithm into C#. 
3.3.3 FIRMS software components 
 The FIRMS software has the following major components: GUI, structural 
modeling algorithm, combinatorial data structure algorithm, IRs calculation algorithm, 
import data and compound structures algorithms, export data algorithms, and simulation 
optimization solver algorithms. 
3.3.3.1 Structural modeling algorithm 
 The molecular structures of organic compounds analyzed by FIRMS are imported 
from PubChem. The process involves extracting molecular structures in canonical 
SMILES format. SMILES is chemical notation language designed for converting an 
arbitrarily selected description of a chemical structure to one distinctive notation. The 
notation is unique in order to preserve the identifier of the specific structure for database 
and other computer applications.199 
 SMILES chemical notations involve a method known as CANGEN which 
combines two separate algorithms, CANON, and GENES. In the first step, CANON 
labels a molecular structure with canonical labels and treats it as a graph with nodes 
(atoms) and edges (bonds). Each atom acquires a unique numerical label based on its 





diagram of the molecular graph. The GENES choose the starting atoms, and builds and 
makes decisions in reference to the canonical labels as required. These two processes 
designate a unique SMILES notation for every chemical structure irrespective of the 
existence of many possible equivalent descriptions of the structures.199 An example of 
SMILES is shown below using the structure of vardenafil. 
 
Figure 3.20. Conversion of vardenafil into SMILES. 
 
The SMILES format of the molecule is then converted to a 2D Chemical Markup 
Language (CML) format using the Open Babel utility. CML was developed by Murray-
Rust et al.,200 as an operational system for managing complex chemical content in 
interoperating XML-based markup languages. It incorporates the CML 1.0 and a 
mechanism that displays CML molecules within a standard web browser. It has 
significant advantages of data recovery capabilities and flexibility over other existing 
computer HTML/plugin solutions.200-202 
Open Babel is an open-source chemical toolbox written in computer codes based 
on languages of chemical data. It provides a platform for multiple chemical file formats 
with additional utilities of 2D depiction, filtering, batch conversion, and substructure and 
similarity searching. Researchers and developers use it as a programming library for 
CCCC1=NC(=C2N1NC(=NC2=O) 
C3=C(C=CC(=C3) S(=O) (=O) 








handling chemical data in disciplines including drug design, organic chemistry, materials 
science and computational chemistry.203 
After the process that involves SMILES, CML and Open Babel, the formatted 2D 
CML information obtained from Open Babel is saved in the FIRMS files directory and 
can be imported into the FIRMS GUI as a new XML file. Once a molecular ions structure 
is imported in FIRMS GUI, the user can select different atoms within the structure to 
associate with fragments observed in the mass spectrum of a molecule. The user also has 
the ability to manipulate the structure to account for rearrangements, multiple bond 
formation, and protonation or deprotonation within a molecular ion. When users are 
satisfied with the structures created, they continue to the next step of producing a model 
that represents the structure. 
3.3.3.2 Combinatorial data structure algorithm 
 The structure selected by the user, which is associated with a fragment in the mass 
spectrum is linked together with the stack data structure algorithm previously discussed 
(Section 3.2.9) to create all accepted combinations of atoms that produce the fragment 
mass observed in the mass spectra. Once these models are created, they are linked to 
tandem mass spec data for further analysis and calculation. 
3.3.3.3 Import data and structure algorithm 
 The FIRMS software allows the user to import data extracted from MS data 
analysis software and link the fragments with the structural models created in the GUI. 
Specifically, the structural fragments drawn by the user are assigned to specific m/z 
values from the mass spectral data. 





 Once the computer models are created and mass spectra are imported into the 
software, the user sets constraints and tolerances and directs the software to initiate the 
numerical solver. At the end of optimization, the FIRMS software displays the results in 
the form of isotope frequencies, their standard deviations, and calculated  values. The 
information obtained by the user can be then be used to characterize the compound in 
order to draw a conclusion. 
3.4 Significance of FIRMS 
 While other IR analysis techniques have been excellent at accurately determining 
IRs, FIRMS was developed in order to compensate for other limitations of these 
techniques. The first important role that FIRMS would play as a new method of IRs 
analysis is the ability to investigate the structure of a molecule under analysis. This is a 
current problem with IRMS and CRDS, in which combustion is necessary to produce a 
gas that is then ionized and measured against standard gases. The standard gases include 
N2, CO2, SO2, and H2O. Due to loss of structure, it is extremely difficult to identify 
compounds in situations where unknown compounds are analyzed. Also, in a mixture of 
several molecules, converting each component into a gas generates problems, because it 
is impossible to associate simple gas molecules produced with a specific compound in the 
mixture. With FIRMS, it is easy to evaluate the IRs of individual molecules of a mixture. 
This is because mass spectral techniques have excellent resolution and sensitivity that can 
be used to identify a molecule. Furthermore, FIRMS relies on mass fragments of 
precursor ions (product ions) to analyze IRs. Every molecule fragments differently in a 
mass spectrometer, which makes identification easier in many cases. On the other hand, 





components of mixtures. Moreover, co-eluting components would theoretically not 
interfere with the IR analysis of each. 
 Secondly, FIRMS reduces the possibility of contamination. NRM, CRDS, and 
IRMS are prone to contamination during sample preparation, and introduction. Standard 
gases might also be contaminated. FIRMS eliminates this problem by targeting a 
particular mass to charge, and uses both precursor and product ions.  
 Third, most IR analysis techniques produce aggregate isotope ratios of the atoms 
present in a molecule. For example, by converting a molecule to CO2, both IRMS and 
CRDS analyze the aggregated value  13C/12C as one number despite the fact that most 
organic compounds have more than one carbon present. FIRMS has the ability to analyze 
each atom or group of atoms separately to determine IRs at specific locations in a 
molecule. 
3.5. Conclusion 
 FIRMS, a nonlinear mathematical model was developed with the potential to 
analyze the isotope ratio of organic compounds. The theorem was proved to be true and 
can model a structure of any organic compound by utilizing FIRMS data structure 
algorithms. Theoretically it has been shown that Evolutionary/Genetic, Tabu and Scatter 
search algorithms are the relevant methods of minimizing the objective functions of 
FIRMS based on full characterization and analysis of FIRMS functions. However, 
Evolutionary (a non-gradient based) algorithm will be used in developing FIRMS and 
will be compared to gradient based Generalized Reduced Gradient (GRG) methods for 
validation. Additionally, computations and data structures proved to be valuable in 





Chapter 4: Analysis of Evolutionary/Genetic Algorithms (EA/GA), Generalized  
Reduced Gradient (GRG) & Multi-start GRG 
4.1. Introduction 
Problems with multiple objectives naturally arise in many disciplines. Calculating 
solutions to these problems is difficult for scientists to this day. Although there are many 
techniques that may solve these problems, the complexity of the mathematical analysis 
involved has influenced the development of alternative approaches. Additionally, some 
MOO problems are so complex that the use of standard multiobjective techniques does 
not provide adequate results. Complexity can manifest as a large search space, 
uncertainty, noise, and discontinuity of Pareto curves. The application of EA/GAs to find 
solutions for MOO problems has been of interest to many researchers. Mainly because of 
their population-based nature, EAs allow the production of several elements of the Pareto 
optimal set in a single analysis. Thus, given the nature and complexity of FIRMS 
functions, three alternative approaches to solving MOO problems were evaluated for their 
performance in solving the FIRMS MOO problem. EA/GA, a non-gradient algorithm, 
GRG (gradient based), and Multistart GRG (gradient based) algorithms were compared to 
evaluate the most appropriate numerical optimization algorithm. As discussed in Chapter 
3, FIRMS functions should require non-gradient based algorithm, and GRG was included 
to test this hypothesis. 
4.2 EA/GA versus GRG  
Frontline Systems Inc. recommends Multistart GRG and Evolutionary algorithms 
for optimization of non-convex and nonsmooth functions, such as FIRMS equations. 





solutions found are local extrema rather than global extrema. However, Multistart GRG is 
capable of evaluating many different locations and initial values within a domain and 
examines the best solution. But both GRG and Multistart GRG require derivatives for 
continuous functions. FIRMS equations of the form 𝑐(𝑥 ) = |𝑓(𝑥 )𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 −
𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙are not differentiable where 𝑐(𝑥 ) =  𝑓(𝑥 )𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 the solution point. 
This is the reason why FIRMS IRs theory argues for non-gradient based optimization 
methods, such as Tabu search, Scatter search and EA/GA. To test this hypothesis, a non-
gradient based algorithm was compared with the performance of gradient-based 
algorithms. Thus, a study was initiated to compare the accuracies of GRG and Multistart 
GRG, gradient-based methods, to the EA/GA non-gradient based method using several 
organic compounds.  
4.3 Evaluation of EA/GA and GRG algorithms using organic compounds 
Several trials were conducted on EMPA, p-toluenesulfonic acid monohydrate and 
5-sulfosalicylic acid dihydrate. The isotope abundance variables were held constant for 
each compound (e.g., 12C, 13C, 1H, 2H, 16O, 17O and 31P for EMPA). Different settings of 
constraints were used based on linear inequalities with varying settings for each type of 
solver. For example, in the Evolutionary solver, the mutation rate was varied between 
0.075 and 0.2 while GRG solver was alternated between the Multistart GRG and standard 
GRG.  
The data used to evaluate the two algorithms were calculated using Equations 5 
and 6 with total abundances for the base mass (M) experimentally determined, and  
values calculated based on Equation 7-10, given an  calculated using Equations 2 and 3. 





values calculated by GRG and EA were then compared to the real  calculated from the 
known isotope abundances of elements. The average, standard deviation, minimum, 
lower quartile, median, upper quartile, maximum, and range of the sum of absolute 
differences from true  values (IRs), and of the sum of absolute differences between the  
values after optimization were analyzed.  
Comparison of the results produced by GRG and Evolutionary algorithms showed 
that the latter outperformed the former. As shown in Table 4.1, the average sum of 
absolute difference between the real  values and those calculated by EA shows that EA 
results were significantly lower, meaning EA results were more accurate than GRG. 
Similar results were observed when evaluating standard deviations, minimum, maximum, 
lower and upper quartile, and median. Moreover, the range of sum of absolute differences 
of   observed were greater for GRG than EA, which means that GRG  values were 
significantly far from the real solution.  
 
Table 4.1. The difference of sum of absolute  values. 
 Sum of absolute  differences 
Compound Algorithm Average Standard 
Deviation 
Minimum Maximum 
EMPA EA 170.7 159.4 9.5 397.9 
GRG 218.8 180.3 56.7 928.3 
p-Toluenesulfonic acid 
monohydrate 
EA 356.0 87.5 257.3 511.2 
GRG 394.3 159.1 200.5 541.5 
5-sulfosalicylic acid dihydrate EA 543.6 134.8 300.5 669.0 







Figure 4.1. A plot of sum of absolute difference of  values (y axis) and  values (x axis) 
for EMPA. The average sum of absolute difference between the real  values and those 
calculated by EA shows that EA results were significantly lower meaning EA results 
were more accurate than GRG. 
 
Figure 4.2. A plot of sum of absolute difference of  values (y axis) and  values (x axis) 





between the real  values and those calculated by EA shows that EA results were 
significantly lower meaning EA results were more accurate than GRG. 
 
 
However, finding accurate solutions did not mean that EA minimized the 
objective function better than GRG algorithms. On the contrary, as shown in Figures 4.1 
and 4.2, for the same analysis GRG methods minimized the objective functions to the 
lower values than EA algorithms. The small difference between calculated and 
experiment  suggested that GRG algorithms are sometimes better in terms of 
optimization performance. 
 Figure 4.3 shows the  differences of different trials, indicating that the EA and 
GRG algorithms appear to have similar or parallel characteristics, with EA performing 
better than GRG. For each adjacent pair of GRG data, the first is regular GRG and the 
second is Multistart GRG. And for an adjacent pair of EA, the first is Evolutionary with 
mutation rate 0.075, and the second is Evolutionary with mutation rate 0.2. This figure 
shows that individual configuration and changing different parameters may improve or 
give undesired results. For example, for trial 4, the mutation rate of 0.2 produced  






Figure 4.3. The  differences for 5-sulfosalicylic acid dihydrate against the trial numbers. 
Each pair of data have different parameters being tested. It shows that individual 





Overall, the solutions found using the Evolutionary algorithm were more accurate 
compared to solutions produced by GRG algorithms. However, some of the GRG minima 
for  were smaller than the minima calculated by EA/GA. However, Figure 4.3 also 
shows that EA/GA solutions were more accurate compared to GRG. The reason for this 
observation is because EA/GA tends to find solutions corresponding to more gradual 
declines that revolve around the true solution. On the other hand, GRG appears to find 
steep and narrow troughs that may exist far from the true solution. Thus, EA/GA was 







Chapter 5: Materials and Method 
5.1 Reagents and Standards 
Ammonium hydroxide, methanol, ethanol, isopropyl alcohol, acetonitrile and 
acetone (HPLC-grade or higher), formic acid, o-phosphoric acid hydrochloric acid, and 
acetylsalicylic acid were purchased from Thermo Fisher Scientific (Ward Hill, MA, 
USA). Ethyl methylphosphonic acid (EMPA) was acquired from Cerilliant (Round Rock, 
TX, USA). 3-chloro-2-nitrobenzoic acid, 2,3-dicyanohydroquinone, L-histidine 
monochloride, L-tyrosine, o-tert-butyl-L-tyrosine, eugenol, caffeine, 3,4-dibromo 
benzaldehyde, 3-phenylpropionic acid, 4-nitrobenzaldehyde, p-toluene sulfonic acid 
monohydrate, tert-butyl chloride, and caffeine were acquired from Sigma-Aldrich (St. 
Louis, MO, USA). Diisopropyl methylphosphonate (DIMPA) and p-toluene sulfonyl 
chloride were purchased from Acros Organics (Morris Plains, NJ, USA). 5-chloro-2-
methylbenzoic acid was purchased from both Sigma-Aldrich (St. Louis, MO, USA) and 
Alfa Caesar (Tewksbury, MA, USA).  
5.2 Sample preparation 
 Compounds were dissolved in various solvents, as shown in Table 5, to produce 5 
mM stock solutions. The solutions were further diluted to create standards with 
concentrations between 60 and 100 M for analysis using DLSI-MS-MS, and LC-MS-MS. 
 In general, FIRMS analysis included four major steps: 1) the analysis of a 
compound using MS to identify fragments and transitions of interests; 2) the collection of 
MS-MS data using DLSI and/or chromatography; 3) converting the MS-MS data to the 
FIRMS format, including selection of fragments, boundaries, and constraints, and 4) 










1 Acetylsalicylic Acid Ethanol 100 
2 Caffeine Acetone 100 
3 5-chloro-2-methylbenzoic acid1 Methanol 100 
4 5-chloro-2-methylbenzoic acid2 Methanol 100 
5 3,4-dibromo benzaldehyde Methanol 100 
6 2,3-dicyano hydroquinone Methanol 100 
7 Diisopropyl methyl phosphonic acid3 Water 60 
8 Diisopropyl methyl phosphonic acid4 Water 60 
9 Ethyl methyl phosphonic acid Water 60 
10 Eugenol Methanol 60 
11 L-Histidine  Water 100 
12 4-nitrobenzaldehyde Methanol 100 
13 3-Phenylpropionic acid Methanol 70 
14 o-tert-butyl-L-Tyrosine Aqueous Formic Acid (1 mM) 70 
15 L-tyrosine Aqueous Formic Acid (1 mM) 100 
16 p-Toluene sulfonyl chloride Methanol 100 
17 p-toluene sulfonic acid  Methanol 80 
1China, 2India, 3France, 4Great Britain 
 
5.3 Direct liquid sample introduction analysis (DLSI) 
 The standards prepared according to Table 5.2 were analyzed using an AB Sciex 
Q-trap 5500 MS-MS (Applied Biosystems, Foster City, CA, USA) DLSI to acquire 
precursor and product ions scans. The standards were introduced using a 1 mL Luer Lock 
Gastight Syringe (Hamilton Robotics, Reno, NV, USA). The declustering potential (DP) 
and collision energy (CE) were optimized for product ions (fragments) of interest. A 
multiple reaction monitoring (MRM) method was developed using the optimized 
parameters and used to detect MRM product ions in either negative or positive polarity, 
depending on the compound being analyzed. For example, MRM transitions for L-histidine 





each for a total of 10 minutes at a flow rate of 10 L/min for five different days. At the end 
of each sample analysis, product ion abundances of each transition for the compounds were 
extracted as text files for analysis using the FIRMS software.  
Table 5.2. MRM transitions for L-histidine monochloride including declustering potential 
(DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion(Da) Product ion (Da) DP(volts) CE(volts) 
156.0 56.0 79.83 44.91 
156.0 66.1 91.74 58.37 
156.0 83.0 46.61 34.49 
156.0 93.1 75.56 30.41 
156.0 110.0 18.49 18.15 
157.0 56.1 26.46 54.74 
157.0 57.0 80.62 48.90 
157.0 66.1 19.34 57.36 
157.0 67.0 59.12 53.56 
157.0 83.1 40.31 36.27 
157.0 84.0 58.27 36.79 
157.0 93.0 17.55 37.06 
157.0 94.1 20.34 31.02 
157.0 110.1 66.81 17.81 
157.0 111.1 60.12 17.51 
 
 
5.4 LC-MS-MS analysis 
Liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) experiments 
were conducted for five different (sometime consecutive) days to evaluate the applicability 
of FIRMS when performing separation via LC. A Shimadzu HPLC (LC-20AD, Shimadzu 
Corp., Kyoto, Japan) was coupled to the AB Sciex Q-Trap 5500 MS. MRM parameters, as 
described in Section 5.3, were used. Caffeine, acetylsalicylic acid and, DIMPA were 






Table 5.3. LCMSMS MRM transitions for caffeine including declustering potential (DP) 
and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
194.6 69.1 178.97 36.29 
194.6 83.1 208.00 37.50 
194.6 110.1 168.12 33.58 
194.6 138.1 49.910 33.30 
195.6 69.1 166.05 26.59 
195.6 70.1 88.870 44.46 
195.6 83.0 114.51 42.85 
195.6 84.1 111.51 57.76 
195.6 110.1 70.930 32.21 
195.6 111.1 122.97 43.45 
195.6 138.1 27.190 26.33 
195.6 139.1 100.56 26.69 
 
Table 5.4. LCMSMS MRM transitions for acetylsalicylic acid including declustering 
potential (DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
179.0 59.0 -57.72 -14.22 
179.0 93.0 -40.49 -31.42 
180.0 59.0 -52.77 -39.56 
180.0 60.0 -69.90 -30.03 
180.0 93.0 -20.25 -32.03 
180.0 94.0 -28.66 -31.44 
 
The LC separation was carried out using a C8 (ZORBAX Eclipse XDB-C8, 5 µM 
4.6 x 150 mm) reversed-phase column (Agilent, USA) with analytical guard column C8 
(ZORBAX 4.6 x12.5 mm 5-Micron). The analytes were eluted isocratically at a flow rate 
of 0.25 mL/min with 25.0%, 25.0%, 50.0% and 0.1% (v/v) isopropyl alcohol, acetonitrile, 
water and formic acid204 respectively. The DIMPA LC method generally followed the 
method of Appel et al.205 using transitions in Table 5.5 shown below. The isotope 





of peak elution above noise and summing the abundances within the time range. The 
abundances were analyzed using FIRMS software in order to calculate isotope ratio values. 
Table 5.5. LCMSMS MRM transitions for DIMPA originating from France including 
declustering potential (DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
181.1 79.0 36.65 46.18 
181.1 97.0 67.71 25.35 
182.1 79.0 43.51 44.40 
182.1 80.0 77.66 44.03 
182.1 97.0 35.70 20.60 
182.1 98.0 43.27 18.48 
 
Table 5.6. LCMSMS MRM transition for DIMPA originating from Great Britain including 
declustering potential (DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
181.1 79.0 30.46 47.00 
181.1 97.0 111.24 18.73 
182.1 79.7 112.78 50.05 
182.1 80.0 86.48 56.43 
182.1 96.9 4.600 12.62 
182.1 97.9 4.840 11.55 
 
5.5 IRMS analysis 
 Pure compounds of interest (Table 5.1) were analyzed via IRMS. Solid compounds 
were ground through a 2-mm screen with a centrifugal grinding mill (Retsch ZM-1, 
Brinkmann Instrument Co., Westbury, NY, USA). Samples (3 mg each) were analyzed for 
total C and 13C isotope abundance (13C relative to total 12C + 13C) on a 20-20 Europa isotope 
ratio mass spectrometer (Europa Scientific Ltd., Crewe, Cheshire, UK). Compounds which 
are liquid at room temperature were mixed with 3 mg Chromosorb W and analyzed for 





samples. The standard used for solid samples was bleached all-purpose wheat flower 
purchased from a local market source with standard values previously verified through 
multiple testing labs. The standard used for liquid samples, Fish tissue, was obtained from 
the Natural Resource Management department at South Dakota State University, and was 
previously verified through multiple testing labs. 
5.6 FIRMS software   
 Genetic Algorithm (GA), Tabu Search (TS) and Scatter Search (SS) algorithms 
were acquired from Frontline Systems Inc. (Incline Village, NV USA) and used to 
minimize the objective function (i.e., differences between the calculated and 
experimental  values (Equation 21) produced from the tandem MS, LC-MS-MS and 
GC-MS-MS data). The minimization was performed twenty times on the data collected 
for each day. For each data set, the 13C was calculated by averaging twenty calculated 
13C values produced by FIRMS algorithms. A 13C value was only included on the 
average when the EA algorithm produced a “converged” solution and the objective 
function value was lower than the original objective value function. The average 13C 
value was calculated from isotope abundance of all five data sets. The isotope 
abundances for the multi-objective optimization (MOO) problems were reported as ∂13C 










Chapter 6: Results and Discussion 
6.1 Mass Spectrometry 
Mass Spectra and Molecular Ion Fragmentation for FIRMS 
 Multiple compounds (N = 17) were evaluated both by FIRMS and IRMS to 
quantify the performance of FIRMS compared to the current “gold standard” technique 
for measuring isotope ratios (i.e., IRMS). The relative abundances of tandem MS product 
ions were analyzed using the FIRMS software. Selected MS spectra of these compounds, 
including IMPA and p-Toluenesulfonic acid monohydrate and their identified fragments 
are discussed below. They include precursor ion and product ion scans for molecular ions 










































Figure 6.1. Simplified tandem mass spectral data for isopropyl methylphosphonic acid 
(IMPA). (A) Precursor ion scan (Q1- scan) of IMPA showing the molecular ion. (B) 
Product ion scan of m/z = 137. (C) Product ion scan of m/z = 138.1. The differences 
between the product ion scan of the base mass (m/z = 137) and the heavier stable isotope 








































































































































































Figure 6.2. Simplified tandem mass spectral data for p-Toluenesulfonic acid 
monohydrate. (A) Precursor ion scan (Q1-scan) of p-Toluenesulfonic acid monohydrate. 
(B) Product ion scan of m/z = 171.1. (C) Product ion scan of m/z = 172.1. The 
differences between the product ion scan of the base mass (m/z = 171.1) and the heavier 
stable isotope (m/z = 172.1) can be attributed to the isotope ratios of the atoms involved.  
 
 
The fragmentation of precursor ions during FIRMS analysis was achieved through 
collision-induced dissociation (CID) in the MS after initial ionization of precursor ions. 
These ions were either negatively charged or positively charged. For example, IMPA, 
EMPA and acetaminophen have molecular weights of 138.103 g/mol, 124.076 g/mol and 
151.165 g/mol, respectively. Their molecular formulas are C4H11O3P, C3H9O3P, and 
C8H9NO2, respectively. However, deprotonation occurs during ionization or before 




-, respectively. DIMPA has a molecular weight of 












































m/z which means that DIMPA undergoes protonation to form a molecular ion 
C7H18O3P
+. Other compounds, such as L-histidine chloride, and p-Toluenesulfonic acid 
monohydrate lost larger fragments during precursor ion filtration, losing chlorine and 
water, respectively.  
Some of the products ions, such as caffeine ions, were produced by rearrangement 
of molecular ions. The rearrangements of compounds generally included conversion of 
single bonds to double or triple bonds, conversion of straight chain carbons to a ring or 
opening of a ring to form straight chain carbons.  
Given that the abundances correlate with isotope ratios and isotope frequencies as 
mentioned in Chapter 3, the MS data were used to calculate the unknown isotope values 
shown in Section 6.4. The FIRMS software was used to calculate the isotope abundance 
values 13C of compounds measured in parts per mil based on complex mathematical 
formulation and numerical minimization. As shown in Section 6.3, FIRMS data were 
accurate with excellent precision and accuracy (measured as an absolute error), < 1‰ and 
< 1.6‰ compared to IRMS values, respectively. This precision is within the generally 
accepted isotope abundance precision range of  1‰ for 13C.117  The R2 (coefficient of 
determination) shown by a bivariate plot of IRMS versus FIRMS technique of the 
compounds was 0.992 with a slope of 1, as shown in Figure 6.6. FIRMS showed both 
good precision and accuracy versus the “gold standard” of IRMS, validating it as an 








6.2 FIRMS LCMSMS  
 Three compounds, acetylsalicylic acid, caffeine and DIMPA were analyzed using 
liquid chromatography. The data were collected over a period of 5 days in order to 
evaluate day-to-day variability of the isotope ratios calculated by FIRMS. Figures 6.3, 
6.4, and 6.5 show single day triplicate liquid chromatograms of DIMPA, acetylsalicylic 








































Figure 6.3. A) Liquid chromatograms of DIMPA originally from France for 181 m/z 















































































Figure 6.4. A) Liquid chromatograms of acetylsalicylic acid for 179 m/z transitions. B) 













































































Figure 6.5. A) Liquid chromatograms of caffeine for 195 m/z transitions. B) Caffeine 
chromatograms for 180 m/z transitions. 
  
 The use of chromatography to separate complex samples prior to MS-MS analysis 
open up FIRMS to a much wider application space. Although FIRMS-LCMSMS is 
theoretically possible, the typical LC peak only allows data collected for a short period of 
time, compared to 10 minutes of DLSI method. Therefore, the error associated with 
LCMSMS may be larger than FIRMS DLSI-MSMS. For example, LC method for 
caffeine involved analysis of peak abundance between 6.5 and 7.5 minutes. This was 
compared to caffeine abundances data acquired via DLSI method for 10 minutes.  
The DIMPA, acetylsalicylic acid and caffeine chromatograms used for FIRMS 
analysis were non-smooth and lack sharpness required for chromatographic research 
work. There was also presence of tailing observed. In general, this would be a concern, 










































quality of chromatograms. Thus, it was concluded that acetylsalicylic acid, caffeine and 
DIMPA chromatograms provided the required data despite the peak shapes. The isotope 
abundance values calculated using LC data were significantly accurate with good 
precision of  1‰, and accuracy of < 1‰ compared to IRMS values.  
LC method results show that the overall accuracy was excellent compared to 
DLSI method of the same compounds. Although we hypothesized that we will observe 
lower accuracy compared to DLSI method the opposite was established with LC method. 
We had expected lower accuracy because of the fact that collecting data over 10 minutes 
gradually minimizes error by normalizing peak abundance values. Peaks analyzed over a 
short amount of time are likely to have larger errors. Thus, the LC method results would 
show slightly inaccurate data compared to IRMS and DLSI-FIRMS method. Because the 
precision and accuracy for 13C were  1‰, and because there was a small difference 
between LCMSMS-FIRMS results and IRMS, FIRMS can be coupled with LC methods 
to analyze a single compound or a mixture of compounds.  
6.3 Isotope ratio calculations by FIRMS  
All data collected using various sample methods, including DLSI, HPLC and GC, 
were analyzed using FIRMS. As shown in Table 6.1, the precision and accuracy of 13C 
measured by FIRMS method were < 1‰ and < 1.6‰ hence meeting the standard 
requirements. These precisions significantly matched IRMS values or showed better 
precisions in some circumstances. 
 FIRMS isotope abundance values were relatively accurate as compared to IRMS 





FIRMS versus IRMS for a total of 17 compounds produces a coefficient of determination 
(R2) of 0.992 and a slope of 1. The R2 and slope of 1 demonstrated the validity of FIRMS.  
















1 Acetylsalicylic acid -30.13 0.10 -30.29 0.27 -0.16 
2 Caffeine -30.11 1.58 -30.28 0.50 -0.17 
3 5-chloro-2-methylbenzoic acid1 -29.01 0.35 -28.74 0.22 +0.27 
4 5-chloro-2-methylbenzoic acid2 -29.14 0.67 -29.03 0.41 +0.11 
5 3,4-dibromo benzaldehyde -27.20 0.23 -27.83 0.65 -0.63 
6 2,3-dicyano hydroquinone -36.11 0.07 -36.26 0.73 -0.15 
7 Diisopropyl methyl phosphonic acid3 -31.80 0.33 -31.40 0.68 +0.41 
8 Diisopropyl methyl phosphonic acid4 -31.06 0.07 -31.35 0.59 -0.30 
9 Ethyl methyl phosphonic acid -33.57 0.10 -32.80 0.27 +0.77 
10 Eugenol -31.82 0.56 -30.86 0.34 +0.96 
11 L-Histidine -7.483 0.10 -7.240 0.65 +0.24 
12 4-nitro benzaldehyde -30.21 0.19 -30.72 0.57 -0.51 
13 3-phenylpropionic acid -27.27 0.05 -27.95 0.44 -0.68 
14 O-tert-butyl-L-tyrosine -21.46 0.00 -20.87 0.40 +0.59 
15 L-tyrosine -26.02 0.05 -26.62 0.46 -0.60 
16 p-toluene sulfonic acid -26.45 0.02 -27.50 0.69 -1.05 
17 p-toluene sulfonyl chloride -27.76 0.00 -27.76 0.42 0.00 
1China,2India,3France,4Great Britain 
 
Table 6.2. Results of FIRMS-LCMSMS 13C, standard deviations, accuracy (absolute 









1 Acetylsalicylic Acid -30.06 -0.07 0.64 
2 Caffeine -29.76 +0.35 0.66 
7 Diisopropyl methyl phosphonic acid1 -31.37 +0.43 0.85 
8 Diisopropyl methyl phosphonic acid2 -30.30 -0.76 0.15 








6.4 Isotope Ratios Mass Spectrometry (IRMS) analysis versus FIRMS 
 In order to validate FIRMS method for 13C calculations, several compounds 
were analyzed using IRMS. The average  values, standard deviations and %RSD of 
those compounds are represented in the Table 5.5 below. These results showed good 
precisions of  1‰ with % RSD  6%.  
Table 6.3. Results of IRMS ∂13C, standard deviations, and RSD 
# Compound IRMS 13C (‰) SIRMS (‰) 
1 Acetylsalicylic acid -30.13 0.10 
2 Caffeine -30.11 1.58 
3 5-chloro-2-methylbenzoic acid1 -29.01 0.35 
4 5-chloro-2-methylbenzoic acid2 -29.14 0.67 
5 3,4-dibromo benzaldehyde -27.20 0.23 
6 2,3-dicyano hydroquinone -36.11 0.07 
7 Diisopropyl methyl phosphonic acid3 -31.80 0.33 
8 Diisopropyl methyl phosphonic acid4 -31.06 0.07 
9 Ethyl methyl phosphonic acid -33.57 0.10 
10 Eugenol -31.82 0.56 
11 L-Histidine -7.483 0.10 
12 4-nitro benzaldehyde -30.21 0.19 
13 3-phenylpropionic acid -27.27 0.05 
14 O-tert-butyl-L-tyrosine -21.46 0.00 
15 L-tyrosine -26.02 0.05 
16 p-toluene sulfonic acid -26.45 0.02 




 FIRMS showed good accuracy compared to IRMS analysis of the same 
compounds. Figure 6.6 shows a linear relationship between FIRMS and IRMS analysis of 
the same compounds. The high R2 value of 0.992 shows that 99% of the variance is 
accounted for data falling within the regression model indicating a good fit between two 
independent methods. Thus, the bivariate plot of IRMS versus FIRMS validates the 







Figure 6.6. The bivariate plot of IRMS versus FIRMS showing the validation of the 














































Chapter 7: Broader impacts, Conclusion and Future Work 
7.1. Broader impacts 
FIRMS is an analytical technique that should expand IR research to any scientist 
with access to a tandem MS. Unlike the current approaches, where IR analysis is available 
to a relatively small number of facilities that can afford to purchase, staff, and maintain IR 
analysis instruments, the tandem MS instruments are more readily available. Moreover, 
FIRMS can be directly coupled to analytical separation techniques, such as LC and GC, to 
aid in determination of IRs of compounds from complex mixtures without the need for 
combustion. The disciplines that will benefit from development of FIRMS include: 1) 
forensic science, 2) environmental chemistry, 3) geology, 4) geochemistry, 5) 
cosmochemistry, 6) food sciences, 7) earth science, and 8) pharmaceutical science. FIRMS 
will make IR analysis more widely available and less expensive for scientists to conduct 
research in these fields, as well as train new graduate students for future scientific research 
and development in this area. 
 
7.2. Conclusion 
FIRMS was developed as a novel laboratory based analytical technique for the 
analysis of 13C and 15N isotope ratios with the potential for simultaneously analyzing 
other isotopes, such as 2H, 18O, 34S, 81Br, and 37Cl, with further development. This 
technique also showed the ability to accurately calculate IRs when coupled with LC. 
FIRMS showed excellent precision and accuracy compared to IRMS, validating FIRMS 
as an accurate isotope ratio measurement technique. FIRMS is relatively economical, 





structural information for organic compounds, is self-standardizing, and can 
simultaneously evaluate IRs for a mixture of compounds. Moreover, FIRMS uses MS-
MS technology, which has the ability to detect nM concentrations and is more readily 
available than IRMS. 
7.3 Future work 
 FIRMS is still a work in progress that requires more data collection and improved 
modeling. Future research should include analysis of isotope ratios of mixtures separated 
by LC and GC. It should also involve analysis of FIRMS functions as a multi-objective 
optimization problem rather than single objective optimization problem. FIRMS’s full 
potential will only be realized with extension to the simultaneous analysis of 2H and 
other isotopes, such as 2H, 15N, 18O, 34S, 81Br, and 37Cl. Thus, future work should 
expand FIRMS analysis of other isotopes. Eventually, a comprehensive study of FIRMS 
applications to other disciplines including: 1) forensic science, 2) environmental 
chemistry, 3) geology, 4) geochemistry, 5) cosmochemistry, 6) food sciences, 7) earth 















All MRM method tables for all compounds analyzed by FIRMS including the one  
that were not validated using IRMS. 
 
Table 1. MRM method for p-toluene sulfonyl chloride including declustering potential 
(DP) and collision energy (CE) measured in volts (V). 
 
 
Precursor Ion Product Ion DP(V) CE(V) 
190.2 65.0 64.75 68.21 
190.2 77.1 238.4 87.44 
190.2 91.1 277.9 36.54 
190.2 144.2 264.36 27.52 
190.2 160.1 226.51 38.77 
191.1 65.0 14.73 55.56 
191.1 65.9 74.16 60.20 
191.1 77.1 79.53 61.73 
191.1 78.1 167.29 70.66 
191.1 143.9 228.52 24.98 
191.1 145.1 195.97 31.54 
191.1 160.1 48.44 20.22 
191.1 161.1 210.34 12.72 
 
 
Table 2. MRM method for Eugenol including declustering potential (DP) and collision 
energy (CE) measured in volts (V). 
 
 
Precursor Ion Product Ion DP(V) CE(V) 
164.2 78.0 90.35 35.22 
164.2 91.0 150.4 31.89 
164.2 94.0 159.18 47.68 
164.2 103.1 163.4 29.68 
164.2 131.1 175.03 22.19 
165.2 78.0 156.86 42.65 
165.2 79.0 154.41 32.48 
165.2 91.1 159.8 38.25 
165.2 92.1 154.39 33.81 
165.2 94.1 152.32 38.85 
165.2 95.0 157.46 30.27 
165.2 103.1 158.65 35.35 
165.2 104.1 174.72 29.29 
165.2 131.1 152.13 32.38 





Table 3. MRM method for o-tert-butyl-l-tyrosine including declustering potential (DP) and 
collision energy (CE) measured in volts (V). 
 
 
Precursor Ion Product Ion DP(V) CE(V) 
238.3 57.0 66.78 51.44 
238.3 91.1 60.17 61.39 
238.3 119.1 27.90 37.69 
238.3 123.1 103.43 35.26 
238.3 136.1 62.84 22.90 
238.3 165.0 50.47 16.69 
239.2 57.2 144.41 52.81 
239.2 58.1 61.38 75.01 
239.2 91.1 51.08 74.89 
239.2 92.0 13.14 44.58 
239.2 119.2 92.64 42.61 
239.2 120.1 43.14 38.17 
239.2 123.0 79.30 30.11 
239.2 124.1 104.57 37.83 
239.2 136.1 67.84 22.69 
239.2 137.1 43.15 21.15 
239.2 165.1 76.93 19.38 
239.2 166.0 58.06 18.73 
 
 
Table 4. MRM method for L-tyrosine including declustering potential (DP) and collision 
energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
182.1 91 35.56 40.22 
182.1 125.8 157.37 24.64 
182.1 153.7 115.37 7.98 
182.1 164.9 54.84 13.71 
183.1 91.0 66.62 40.45 
183.1 92.1 37.69 41.74 
183.1 125.9 14.19 9.49 
183.1 126.9 87.78 9.25 
183.1 153.8 178.88 63.46 
183.1 155.2 177.09 13.34 
183.1 165.1 81.86 14.03 









Table 5. MRM method for 3-phenyl propionic acid including declustering potential (DP) 
and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
150.0 91.1 83.56 31.89 
151.2 91.1 60.23 26.07 
151.2 92.1 118.09 32.53 
 
 
Table 6. MRM method for p-toluene sulfonic acid including declustering potential (DP) 
and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
171.0 77.1 -57.80 -47.07 
171.0 79.9 -41.81 -25.87 
171.0 106.9 -37.64 -26.59 
172.0 77.1 -107.68 -37.19 
172.0 78.0 -110.78 -31.93 
172.0 79.9 -100.41 -42.31 
172.0 80.9 -84.30 -39.86 
172.0 107.0 -13.53 -30.07 
172.0 108.1 -81.30 -27.07 
 
 
Table 7. MRM method for 3, 4-dibromo benzaldehyde including declustering potential 
(DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
263.1 75.0 260.61 65.67 
263.1 79.1 166.37 73.65 
263.1 105.2 205.72 60.62 
263.1 156.0 214.05 41.60 
263.1 234.9 223.54 36.82 
264.2 75.1 269.37 80.79 
264.2 76.0 270.78 75.59 
264.2 105.1 4.81 54.28 
264.2 106.1 67.83 61.81 
264.2 156.0 226.68 46.85 
264.2 157.0 249.22 49.46 
264.2 234.9 223.81 38.67 









Table 8. MRM method for 2, 3-dicyano hydroquinone including declustering potential 
(DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
159.7 77.0 -139.91 -29.44 
159.7 105.0 -137.31 -31.43 
159.7 131.0 -147.10 -33.15 
161.2 77.0 -138.49 -28.05 
161.2 77.9 -131.04 -24.90 
161.2 105.1 -158.6 -17.12 
161.2 106.1 -145.99 -33.40 
161.2 131.0 -130.58 -37.69 
161.2 132.0 -133.07 -32.73 
 
 
Table 9. MRM method for 4 – nitro benzaldehyde including declustering potential (DP) 
and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
150.0 76.0 -139.58 -32.08 
150.0 92.1 -33.54 -17.34 
150.0 121.9 -36.50 -6.25 
151.1 76.1 -131.08 -19.05 
151.1 77.2 -24.90 -25.80 
151.1 92.1 -50.54 -33.75 
151.1 93.1 -34.80 -29.31 
151.1 121.9 -61.36 -16.36 
151.1 122.8 -30.09 -15.94 
 
Table 10. MRM method for 5-chloro-2methyl benzoic acid originating from China 
including declustering potential (DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
171.1 91.0 23.68 26.07 
171.1 125.1 91.38 34.26 
171.1 141.3 254.36 52.34 
171.1 153.1 21.33 26.80 
172.1 91.0 235.06 48.73 
172.1 92.1 69.39 34.71 
172.1 125.1 98.35 19.10 
172.1 125.9 51.98 26.49 
172.1 141.0 276.6 86.63 
172.1 141.9 224.73 64.70 
172.1 153.3 139.26 27.33 






Table 11. MRM method for 5-chloro-2methyl benzoic acid originating from India 
including declustering potential (DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
171.2 91.0 77.31 32.25 
171.2 125.1 124.5 35.06 
171.2 141.2 253.75 59.62 
171.2 153.1 23.65 23.39 
172.2 91.1 138.67 32.68 
172.2 92.0 105.51 31.64 
172.2 125.0 18.12 27.13 
172.2 126.0 23.81 52.30 
172.2 141.1 250.6 104.16 
172.2 142.1 241.26 49,97 
172.2 153.3 66.05 60.11 
172.2 154.1 78.98 19.30 
 
 
Table 12. MRM method for ethyl methyl phosphonic acid including declustering potential 
(DP) and collision energy (CE) measured in volts (V). 
 
Precursor Ion Product Ion DP(V) CE(V) 
123.0 77.0 -23.56 -17.87 
123.0 78.9 -14.48 -29.61 
123.0 94.9 -19.25 -11.93 
123.9 76.7 -18.49 -36.80 
123.9 77.8 -106.16 -32.07 
123.9 78.9 -54.56 -38.24 
123.9 79.9 -48.23 -36.41 
123.9 94.8 -62.35 -16.54 
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